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Human central nervous system (CNS) tumors are a heterogeneous group of neoplasms 
occurring in brain, brainstem and spinal cord. Malignant gliomas, which arise from the 
neuroepithelial cells, are the most common CNS neoplasms in human. Malignant gliomas are 
highly aggressive and invasive tumors, and have a very poor prognosis. The development and 
progression of gliomas involve a stepwise accumulation of genetic alterations that affect 
signal transduction pathways activated by receptor tyrosine kinases (RTKs). Constitutive 
activation or deregulated signaling by RTKs is caused by gene amplification, overexpression 
or mutations, and may lead to the activation of several downstream pathways, and ultimately 
to cell transformation and tumor proliferation.    
 
Many genetic abnormalities implicated in nervous system tumors involve the genes located at 
the chromosomal region 4q12. This locus harbors the receptor tyrosine kinases KIT, PDGFRA 
and VEGFR2, and other genes (REST, LNX1) with neural function. Gene amplification and 
protein expression of KIT, PDGFRA, and VEGFR2 was studied using clinical tumor material. 
REST and LNX1, as well as NUMBL, the interaction partner of LNX1, were studied for their 
gene mutations and amplifications. In our studies, amplification of LNX1 was associated with 
KIT and PDGFRA amplification in glioblastomas, and coamplification of KIT, PDGFRA and 
VEGFR2 was observed in medulloblastomas and CNS primitive neuroectodermal tumors. 
PDGFRA amplification was also correlated with poor overall survival. Coamplification of 
KIT, PDGFRA and VEGFR2 was observed in a subset of human astrocytic and 
oligodendroglial tumors. We suggest that genes at 4q12 could be a part of a larger amplified 
region, which is deregulated in gliomas, and could be used as a prognostic marker of 
tumorigenic process. The signaling pathways activated due to gene amplifications, activating 
gene mutations, and overexpressed proteins may be useful as therapeutic targets for glioma 
treatment.  
 
This study also includes the characterization of KIT overexpressing astrocytes, analyzed by 
various in vitro functional assays. KIT and its ligand SCF, a stem cell factor, are widely 
expressed in embryonic and adult mouse brain, and they play an important role in many signal 
transduction pathways involved in cellular proliferation and differentiation. However, the 
function of KIT in glial tumorigenesis and disease progression remains mostly unknown. Our 
results show that overexpression of KIT in mouse astrocytes promotes cell proliferation and 
anchorage-independent growth, as well as phenotypic changes in the cells. Furthermore, the 
increased proliferation is partly inhibited by imatinib, a small molecule inhibitor of KIT. 
These results suggest that KIT may play a role in astrocyte growth regulation, and might have 




REVIEW OF THE LITERATURE 
 
1 DEVELOPMENT OF CENTRAL NERVOUS SYSTEM (CNS) 
 
1.1 The early development of CNS 
 
In mammalian central nervous system (CNS), neurogenesis precedes gliogenesis; neurons are 
primarily generated at the neural stage, whereas most glial cells are generated perinatally and 
postnatally. Glial cells, such as astrocytes and oligodendrocytes usually outnumber neurons in 
the human brain by 10 to 1, and make up about 50% of the overall volume of the nervous 
system. The principal cell types in the brain, neurons and glia (astrocytes and 
oligodendrocytes), are produced within two adjacent proliferative zones located next to the 
ventricle walls; the ventricular zone (VZ) and the subventricular zone (SVZ) (Mayer-Proschel 
et al., 1997; Rao and Mayer-Proschel, 1997; Wichterle et al., 1999). At the onset of 
neurogenesis, these neuroepithelial cells give rise to radial glia, which express markers such 
as transmembrane protein CD133, vimentin and intermediate filament protein nestin. 
Intermediate progenitor cells (IP), a second population of mitotic cells located in the SVZ, are 
generated by radial glial divisions in the VZ. IP cells differ from radial glial cells by their 
expression of specific transcription markers, such as Svet1 and Tbr2 (Tarabykin et al., 2001; 
Englund et al., 2005). Radial glial cells can self-renew and produce neurons, astrocytes, and 
oligodendrocytes, and may be classified as neural stem cells (NSC), whereas IP cells are 
capable of producing only neurons. Most of the radial glial cells generate neurons during 
neurogenesis, and later give rise to glial cells (Malatesta et al., 2000; Noctor et al., 2004).  
 
During neurogenesis, radial glial cells undergo both asymmetric and symmetric cell divisions 
in order to self-renew as well as produce differentiated neuronal and glial progeny. 
Asymmetric divisions can produce a self-renewing radial glial cell and a daughter cell that 
becomes a neuron, or it can generate two daughter cells that both re-enter the cell cycle, but 
one remains as an apical progenitor cell in the VZ whereas the other moves to the SVZ to 
become a basal progenitor cell. Symmetric divisions can generate either two progenitor cells, 
or two neurons (Noctor et al., 2004). In Drosophila, a key determinant for asymmetric 
daughter cell fates is Numb, which has two mammalian homologs, m-Numb and Numbl 
(Nbl). Numb homologs are localized to the apical side of neural progenitor cells, and they are 
essential for asymmetric divisions that generate a neuron and a daughter progenitor cell 
(Zhong, 1996; Guo et al., 1996). Earlier reports suggested that Numb homologs segregate to 
the progenitor/uncommitted daughter cell, but recent study has suggested that they similarly 




four isoforms with different functions, which may have distinct roles in neurodevelopment 
(Dooley et al., 2003).  
 
The major signaling pathways involved in CNS development and maintenance and 
proliferation of neural stem cells are fibroblast growth factor (FGF) family, epidermal growth 
factor (EGF) family, Wingless (Wnt) family, Notch family, and transforming growth factor-
β/bone morphogenetic protein (TGF-β/BMP) family (Tropepe et al., 1999; Davidson et al., 
2007; Hitoshi et al., 2002; Liem et al., 1997). FGF signaling is one of the earliest known 
pathways involved in neural specification. Members of the FGF family may induce the 
survival and proliferation of the early neural precursors. They can induce Notch signaling 
(Lowell et al., 2006) and antagonize BMP signaling, thus stabilizing the neural identity 
(Zhang, 2004). BMPs are members of TGF-β family, and expression of BMP antagonists like 
noggin and chordin causes neural induction (Gratsch and O'Shea, 2002).  The Wnt signaling 
pathway has been shown to control the self-renewal of NSCs (Walsh and Andrews, 2003), 
and the Notch signaling pathway is required for maintenance and differentiation of NSCs in 
developing brain (Hitoshi et al., 2002).  
 
1.1.1 Neuronal differentiation 
 
During early development, the neuroepithelial cells give rise to radial glia, which later 
migrate into neocortex, where they undergo neuronal differentiation into diverse neuronal 
subtypes. Neural differentiation is promoted by basic helix-loop-helix (bHLH) transcription 
factors, such as neurogenins (Ngns) and Mash1, which activate the expression of neuronal 
bLHL genes NeuroD and Math3 (Cau et al., 2002). Proneural bHLH factors (Ngns, Mash1) 
are expressed in the ventricular zone, where neural progenitors begin differentiation, whereas 
bHLH neuronal differentiation factors (NeuroD, Math3) are expressed by fully differentiated 
neurons in the cortical plate (reviewed in Ross et al., 2003). Hes factors inhibit neuronal 
differentiation by sustaining the neural progenitors in an undifferentiated, proliferative state, 
and the balance between the activity of proneural bHLH factors and Hes factors is important 
in the regulation of progenitor maintenance and neuronal differentiation in the neocortex 
(Ohtsuka et al., 2001). Neurogenesis is also enhanced by CCAAT/enhancer-binding protein 
(C/EBP) transcription factor family, which activate neuronal genes and inhibit gliogenesis 
(Ménard et al., 2002). BMP antagonist noggin can induce neurogenesis directly via Smad1-
mediated signaling, or indirectly by downregulating the BMP target proteins. Wnt signaling 
has been also shown to induce neurogenesis by triggering neuronal differentiation of neural 




1.1.2 Astrocyte and oligodendrocyte differentiation 
 
The glial-restricted progenitors arise from NSCs and generate astrocytes and oligodendrocytes 
(Herrera et al., 2001). The differentiation of the cell lineages occurs through generation of 
progressively more restricted precursor cells (Desai and McConnell, 2000). Astroglial 
differentiation is induced by ciliary neurotrophic factor (CNTF)/leukemia inhibitory factor 
(LIF) family cytokines (Hughes et al., 1988), as well as by basic fibroblast growth factor 
(bFGF) (Grinspan et al., 1993). BMPs can promote astrocyte development either on their own 
(Fukuda et al., 2007), or in synergy with LIF (Gross et al., 1996; Mehler et al., 2000). Wnt 
signaling has been shown to induce BMPs, which in turn promote astroglial differentiation 
and inhibit oligodendroglial differentiation (Kasai et al., 2005). One of the known markers for 
astrocytes is glial fibrillary acidic protein (GFAP), which is also expressed in the stem cells of 
adult mammalian SVZ (Bignami and Dahl, 1977; Doetsch et al., 1997). 
 
Astrocytes have diverse functions in the CNS, including regulation of neuronal growth and 
survival (Arenander et al., 1992; Kornblum et al., 1998), guidance of cell migration and axon 
growth during development (Hatten, 1990; Powell et al., 1997; Komuro and Rakic, 1998), 
promotion of synapse formation and modulation of synaptic transmission (Araque et al., 
1998; Bezzi et al., 1998), and orchestration of inflammatory and immune responses during 
brain infection and injury (reviewed in Aschner et al., 2002). Astrocytes act structurally and 
functionally as sensors and regulators of the local microenvironment in the human CNS 
(Nedergaard et al., 2003), and play a prominent role in controlling the extracellular ion 
concentration, pH homeostasis, and glucose levels, and providing the metabolic substrates 
(reviewed in Gee and Keller, 2005). Astrocytes are also involved in formation of blood-brain 
barrier (Rubin et al., 1991), and they have been associated with several neurodegenerative 
disorders, such as Huntington disease, Alzheimer disease and multiple sclerosis (Shin et al., 
2005; Mouser et al., 2006; Tanuma et al., 2006). 
 
Oligodendrocytes originate from the oligodendrocyte progenitor cells (OPCs) in the 
embryonic ventral telencephalon, and migrate to colonize the gray and white brain matter 
(Menn et al., 2006). Recent studies have shown that oligodendrocytes, which express the 
oligodendrocyte lineage transcription factor 2 (Olig2), can also be generated in the adult SVZ 
(Menn et al., 2006). In addition to Olig2, immature OPCs express Olig1, NG2 proteoglycan, 
platelet-derived growth factor receptor  (PDGFR ), and oligodendrocyte antigen O4 
(reviewed in Wegner et al., 2008, and Nishiyama et al., 2009). As oligodendrocytes mature, 
expression of NG2 and PDGFR  is eventually lost (Pfeiffer et al., 1993). Mature 
oligodendrocytes express components of myelin sheath, such as galactocerebroside and 
myelin basic protein (Nishiyama et al., 2009). Olig1 is important for myelination in the CNS, 
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whereas Olig2 is essential for development of oligodendrocytes and motoneurons, and is 
expressed throughout the CNS during and after development (Cai et al, 2007). Differentiation 
of oligodendrocytes is induced by Sonic Hedgehog (Shh), platelet-derived growth factor 
(PDGF), and insulin-like growth factor-1 (IGF1) signaling pathways (Pringle et al., 1996; 
1997; McKinnon et al., 2005; Hsieh et al., 2004). BMP signaling represses Olig2 expression 
and negatively regulates oligodendrocyte specification (Mekki-Dauriac et al., 2002), whereas 
noggin antagonizes BMPs and promote oligodendroglial differentiation (Kasai et al., 2005). 
Other important factors in oligodendrocyte differentiation are the Sry-box containing (Sox) 
genes, especially Sox10, which is critical for oligodendrocyte maturation (Stolt et al., 2002). 
 
Oligodendrocytes have an important role in providing support for neurons, as well as in 
producing and maintaining the myelin sheath in the CNS. Myelination enables fast electrical 
conduction along the axon, and loss of myelin is involved in many neurological diseases. 
Oligodendrocytes also mediate the metabolic pathways between neurons and the vascular 
system (reviewed in van der Knaap, 2001). 
 
1.2 Adult neurogenesis 
 
A previous view of classical neuroscience was that once development was completed, no new 
neurons were born (Levitt et al., 1981; Luskin et al., 1993). Later experiments have shown 
ongoing neurogenesis in the adult vertebrate brain (Lim and Alvarez-Buylla, 1999; Curtis et 
al., 2007). Two germinal regions within the adult brain have been shown to contain neural 
progenitor cells: the SVZ along the walls of the lateral ventricles, and the subgranular zone 
(SGZ) within the dentate gyrus of the hippocampus (Lois and Alvarez-Buylla, 1993). Most 
recently, cells with stem cell properties have been isolated from the subcallosal area (Seri et 
al., 2006), cerebellum (Lee et al., 2005), and the spinal cord (Dromard et al., 2008). These 
cells are multipotent, giving rise to neurons, astrocytes and oligodendrocytes. 
 
Four different cell types in the SVZ have been described: ependymal cells that are located in 
the ventricle wall, slowly dividing astrocyte-like neural stem cells (type B cells), which give 
rise to actively proliferating, and transitory amplifying progenitor cells (type C cells), which 
further develop to immature neuroblasts, called type A cells (Figure 1). The neuroblasts then 
migrate to the olfactory bulb and differentiate into local interneurons (Lois and Alvarez-
Buylla, 1994; Kornack and Rakic, 2001), regulated by TGF-β (Tropepe et al., 1997). The 
SVZ NSCs exhibit astrocytic properties; they express GFAP (Doetsch et al, 1999), and the 
SGZ NSCs have also prominent radial processes (Seri et al., 2001). Other commonly used 
markers for NSCs of the SVZ are musashi, nestin, PDGFR  and CD133 (reviewed in Jackson 




Sox2 (Carcia et al., 2004; Komitova and Eriksson, 2004). However, these markers are not 
necessarily specific for NSCs. 
 
Both astrocyte-like stem cells (type B cells) and neuroblasts (type A cells) can form 
neurospheres in vitro (Alvarez-Buylla et al., 2001), ability that in combination with self-
renewal capacity is used as an indicator of the stem cell property. Furthermore, brain injury 
induces migration of nestin-positive cells from the SVZ to the site of injury (Johansson and 
Arvidsson, 1994; Weinstein et al., 1996), suggesting that a subset of glial precursors remains 












Figure 1. Representation of the cellular composition and organization of the adult rodent 
neural stem cell niches in the SVZ. A = neuroblast (type A cell), B = astrocyte (type B cell), C 
= transit amplifying cell (type C cell), E = ependymal cell, LV = lateral ventricle. (Modified 






2  DEVELOPMENT OF CNS TUMORS 
 
2.1 Cellular origins of nervous system tumors 
 
The common view over the last decades has been that astrocytomas and oligodendrogliomas 
arise from astrocytes and oligodendrocytes, respectively. Later on, several studies have 
proposed that some human gliomas contain a subset of cells with stem cell-like properties, 
and it has been widely suggested that gliomas arise from these “cancer stem cells” (CSCs). 
However, the CSC hypothesis has recently been challenged, and other possibilities for brain 
tumor initiating cells are under investigation. 
 
The adult CNS harbors NSCs that have common biological features with CSCs; they are 
capable of self-renewal, proliferation and differentiation into mature cell types (neurons, 
oligodendroglia, and astrocytes). The identification of these multipotent and self-renewing 
neural stem cells within the adult CNS, mostly in SVZ (Reynolds et al., 1992; Palmer et al., 
1997; Roy et al., 1999) has lead to a hypothesis that neural stem cells could be the targets of 
transformation in glial tumorigenesis. Normal adult NSCs are mitotically active and have a 
long life span, and would thus be able to accumulate mutations and undergo neoplastic 
transformation. These “CSCs” would then be able to escape the mechanisms that control 
proliferation and differentiation, and subsequently give rise to malignant gliomas. These 
quiescent, self-renewing, and multipotent neural stem cells, which express the astrocytic 
marker GFAP and exhibit other morphological features of astrocytes, are capable of 
responding to growth factors such as EGF and PDGF (Doetsch et al., 1999; Alvarez-Buylla et 
al., 2001; Jackson et al, 2006). TGF-β can induce the self-renewal of glioma-initiating cells 
through the induction of LIF in human glioblastoma (Peñuelas et al., 2009), and other 
pathways classically associated with neural development (Wnt, Notch, Shh, BMPs) have been 
shown to be involved in regulation of brain tumor stem cells (reviewed in Clark et al., 2007). 
 
CSCs have now been isolated from a wide range of CNS neoplasms, including gliomas (both 
adult and pediatric), anaplastic oligodendrogliomas, and malignant medulloblastomas 
(Ignatova et al., 2002; Galli et al., 2004; Hemmati et al., 2003; Singh et al., 2003). The 
isolated cells were multipotent and able to self-renew, and expressed the stem cell marker 
CD133 (prominin) (Singh et al., 2004). Furthermore, they grew as neurospheres in the 
presence of EGF and FGF, and started to differentiate and express neural and glial markers 
after growth factor removal (Ignatova et al., 2002; Singh et al., 2003; Galli et al., 2004). 
However, recent studies show that CD133 expression cannot be used as a unique marker of 




Rebetz et al., 2008), and it is also expressed by other than glioma stem cells (Clément et al., 
2009). 
 
Some studies have presented more committed progenitors cells, such as transitory amplifying 
progenitor cells in the SVZ, as alternative candidates for the cell of origin in gliomas. 
Restricted progenitors are able to proliferate but are generally defined as unipotent. These 
progenitors could acquire the self-renewal potential and mutations that would lead to 
transformation. Kondo and Raff have shown that committed oligodendroglial progenitors can 
reacquire stem-like properties after extensive treatment in vitro (Kondo and Raff, 2000), 
which results in reactivation of the primitive neural epithelial marker Sox2 (Kondo and Raff, 
2004). Sox2 is also expressed in human gliomas (Schmitz et al., 2007), suggesting that similar 
mechanisms could be involved in the process of transformation of a restricted precursor to 
transformed cell type. Multiple studies have shown that early cortical astrocytes can be 
targeted in vitro or in vivo with oncogenes or growth factor stimulation to produce tumors in 
animal models (Ding et al., 2001; Uhrbom et al., 2005; Xiao et al., 2005). Neurospheres 
generated from these genetically modified astrocytes could form gliomas when implanted into 
the brains of severe combined immunodeficient (SCID) mice (Singh et al., 2004). However, 
studies with engineered mouse models have shown that neural stem cells are more permissive 
to the transforming effects than glial progenitor cells (Holland et al., 1998; Alcantara Llaguno 
et al., 2009), and it has been shown that tumor suppressor gene inactivation in neural stem 
cells is necessary and sufficient to induce astrocytoma formation in mouse brain (Groszer et 
al., 2001; Llaguno et al., 2008). 
 
At present, there is no consensus on how to define brain tumor initiating cells or CSCs. One 
of the major limitations in defining the CSCs is the lack of definitive markers for these cells. 
The CSC theory has important therapeutic consequences, since they are relatively resistant to 
cancer therapies; they cycle slowly, express high levels of drug export proteins, and may not 
express or depend on oncoproteins targeted by small molecule inhibitors. Increased drug 
resistance can lead to regrowth of the tumor after treatment. The tumorigenic capacity of 
CSCs is also regulated by hypoxia-inducible factors (HIFs), which are critical to CSC 
maintenance and angiogenic drive, and expression of HIF2α has been shown to associate with 
poor glioma patient survival (Li et al., 2009). Therapeutic strategies that specifically target 
CSCs and associated molecules involved in neoangiogenesis will be necessary for eradication 





2.2 Clinical and molecular epidemiology of gliomas  
 
Malignant gliomas are tumors of the glial or supportive cells in the brain or spinal cord. They 
are the most common primary brain tumors in adults, accounting for approximately 70% of 
all the new cases diagnosed per year. The incidence of malignant gliomas in the USA is 
approximately 3-5 cases per 100,000 persons in a year (CBTRUS, 2006; Louis et al., 2007). 
The prognosis of these tumors is very poor, and the median survival for glioblastoma patients 
is only 10 to 12 months, and 2 to 5 years for patients with anaplastic astrocytoma (reviewed in 
Sathornsumetee and Rich, 2007a). 
 
Malignant gliomas are among the most vascular tumors, and tumor-induced angiogenesis is 
one of the pathological hallmarks of these tumors.  It has been demonstrated experimentally 
that malignant glioma cell growth and survival are dependent on angiogenesis (Folkman, 
1971). Glioma cells produce several angiogenic factors, including vascular endothelial growth 
factor (VEGF) (Plate et al., 1992b), and activation of endothelially expressed vascular growth 
factor receptor 2 (VEGFR2) by VEGF stimulates the endothelial cell growth (Millauer et al., 
1994). Inhibition of angiogenesis is thus a promising therapeutic strategy in glioma treatment. 
 
Gliomas have also a remarkable tendency to infiltrate the surrounding brain. However, glioma 
cells are incapable of penetrating the basement membrane, which explains the lack of 
metastases in gliomas (Bernsten and Woodard, 1995). The invasive abilities are seen in both 
low-grade and high-grade gliomas, implying that the invasive phenotype is acquired early in 
tumorigenesis (Forsyth et al., 1999). In order to migrate, the cell needs to interact with and 
degrade the extracellular matrix (ECM). The most malignant gliomas express a variety of 
integrin receptors that mediate interactions with components of ECM (Giese et al., 1996; 
Deryugina et al., 1996). Proteases involved in ECM degradation include matrix 
metalloproteinases (MMPs), urokinase-type plasminogen activator (uPA), and cystein 
proteases (cathepsin B and L) (Vince et al., 1999; Landau et al., 1994; Rempel et al., 1994), 
and they have been shown to contribute to invasion and tumorigenesis of gliomas (Xia et al., 
2009; McCormick, 1993; Yamamoto et al., 1994). 
 
Most brain tumors have been reported as sporadic events, but some studies have shown the 
familial aggregation of gliomas, medulloblastomas and meningiomas. Some reports suggest 
that familial aggregation is caused by environmental factors (Grossman et al., 1999); others 
have detected common genetic abnormalities in familial gliomas (Paunu et al., 2002). Only 
two relatively rare risk factors for developing gliomas have been identified by far; exposure to 
ionizing radiation and inherited mutations of highly penetrant genes associated with rare 




syndrome, Gorlin’s syndrome, retinoblastoma, and tuberous sclerosis. However, in most cases 
the genetic cause of familial brain tumors is unknown. There is also some evidence of an 
inverse association between immunologic factors, including allergies, autoimmune diseases, 
and antibodies to varicella-zoster virus (VZV), and gliomas (Brenner et al., 2002; Wiemels et 
al., 2004; Wrensch et al., 2005). A variety of other viral and parasitic infections have been 
investigated in relation to increased risk for developing gliomas, but the results remain 
inconclusive (reviewed in Wrensch et al., 2002). 
 
2.3 Genetic instability and gene amplification 
 
The development of nervous system tumors is associated with the acquisition of genetic 
alterations and the corresponding changes in gene expression that contribute to normal growth 
control and survival pathways. The high mutation rate seen in cancer cells is explained by the 
genetic instability, which plays an important role in accumulation of genetic changes 
(reviewed in Lengauer et al., 1998). Genetic instability is common in solid tumors, and it is 
usually detected at the chromosomal level, but sometimes also at the nucleotide level 
(microsatellite instability) (Lengauer et al., 1998). 
 
Cancer cells usually have abnormal numbers or arrangements of chromosomes (aneuploidy), 
resulting from chromosome duplications, from the loss of chromosomal regions, or from 
translocations. Translocation can lead to oncogenic fusion proteins (such as Philadelphia 
chromosome) (Rowley, 1973), or inactivation of tumor suppressor genes. Loss of telomeres 
can result in chromosome rearrangements and gene amplification (Lo et al., 2002). 
Chromosomal instability can also be detected as a loss of heterozygosity (LOH) that is loss of 
one of the parental alleles. LOH of the wild-type allele is a hallmark of tumor suppressor 
genes, and is commonly seen in many tumors, including nervous system tumors (reviewed in 
Vogelstein and Kinzler, 1993). Microsatellite instability is less commonly seen in cancer than 
chromosome instability. Microsatellites are short tandem DNA repeats of 1-6 base pairs (bp) 
in length, scattered throughout the genome (reviewed in Charames and Bapat, 2000). 
Microsatellite instability is caused by defects in the mismatch repair mechanism, which 
results in unstable microsatellites, and the appearance of abnormally long or short 
microsatellites. Genes harboring microsatellites accumulate frameshift mutations during 
replication, which leads to translation of truncated proteins. 
 
Gene amplification is one of the major mechanisms of tumor cell to upregulate and activate 
cellular oncogenes during tumor development and progression. It is frequently observed in 
solid tumors, such as colon, prostate, breast, pancreatic, gastric, and brain cancer (reviewed in 
Albertson et al., 2003). Gene amplification means a copy number increase of a restricted 
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region of a chromosome arm. Amplified DNA can be organized as extrachromosomal 
elements (double minutes), as repeated units at a single locus, or scattered throughout the 
genome (Albertson et al., 2003). The amplified DNA regions can in some cases involve 
sequences from two or more regions of the genome, involving multiple chromosomes (Lafage 
et al., 1992; Difilippantonio et al., 2002), and the amplified region can range in size from 
kilobases to megabases. Gene amplification is likely to be initiated by a DNA double break 
(Coquelle et al., 1997), caused by defective DNA replication, telomere dysfunction, and the 
presence of fragile sites at the genome. Collapse of replication bubbles during DNA 
replication has been proposed to explain the formation of some common amplicons in human 
cancers (Schwab et al., 1995; Vogt et al., 2004; Kuwahara et al., 2004). 
 
Telomeres are DNA-protein complexes that contain short repeat sequences added to the ends 
of chromosomes by a telomerase enzyme, and they have an important function in preventing 
the loss of DNA sequences at chromosome ends during normal DNA replication (reviewed in 
Blackburn, 2001). Telomerase is inactive in most somatic cells, thus in normal cells the 
shortening of telomeres leads to cellular senescence. Most tumor cells have acquired the 
capability to maintain telomere length through reactivation of telomerase, or by using a 
mechanism called alternate lengthening of telomeres (ALT) (Murnane et al., 1994). 
Chromosome rearrangements caused by telomere loss in cancer cells have been proposed to 
result from the extensive chromosome fusion that occurs when telomeres become critically 
short (Rudolph et al., 2001). Amplification as a result of telomere dysfunction is thought to 
occur through breakage-fusion-bridge (BFB), where dysfunctional telomere promotes fusion 
of chromosome ends and formation of a dicentric chromosome (McClintock 1941; reviewed 
in Murnane and Sabatier, 2004). The BFB cycles can continue for multiple cell generations, 
leading to an extensive DNA amplification and ending when the chromosome eventually 
acquires a new telomere, possibly by translocation to another chromosome, and becomes 
stable (Lo et al., 2002; Sabatier et al., 2005). 
 
Some genomic regions have shown to be more prone to amplify than others (reviewed in 
Glover, 2006). Among these sites are the chromosomal fragile sites, which are late replicating 
regions, prone to breakage under replication stress. There are  100 known fragile sites in 
human genome, and they are associated with a high frequency of recombination events 
(Coquelle et al., 1997). Other possible classes of sequences involved in generating amplicons 
include repetitive elements, such as Alu sequences, which may promote amplification through 
inappropriate homologous recombination, long interspersed nucleotide elements (LINE), or 
other short sequences promoting microhomology-mediated joining (Vogt et al., 2004; 





Gene amplifications in human cancers provide a means of overexpression of oncogenes. The 
amplified DNA can serve as a diagnostic marker and an indicator of the presence of tumor-
related candidate oncogenes at the amplified region. Amplification has importance for both 
prognosis and targeted therapies of cancer, and the genes within the amplicons can be used as 
targets in cancer therapy. 
 
2.4 The most common types of CNS tumors 
 
The nervous system tumors are histologically a heterogeneous group. The current World 
Health Organization (WHO) classification divides the CNS tumors into several entities; 
tumors of the neuroepithelial tissue, tumors of cranial and paraspinal nerves, tumors of the 
meninges, tumors of the sellar region, lymphomas and hematopoietic neoplasms, and germ 
cell tumors (Louis et al., 2007). Tumors arising from neuroepithelial tissue include astrocytic, 
oligodendroglial, oligoastrocytic, and embryonal tumors, among others. Schwannomas occur 
in the cranial and paraspinal nerves, whereas meningiomas arise from meningothelial cells of 
the meninges. 
 
Grading of the tumors is based on their mitotic index (growth rate), vascularity (blood 
supply), presence of necrosis, invasive potential (border distinctness) and similarity to normal 
cells. In the WHO grading system, grade I tumors are the least malignant. They grow slowly 
and microscopically appear almost normal. Surgery alone may be effective for grade I tumors, 
and they are often associated with long-term survival. Grade II tumors show increased 
mitogenic potential than grade I tumors, and have a slightly abnormal microscopic appearance 
(nuclear atypia). These tumors may invade surrounding normal tissue, and may recur as a 
grade III or higher tumors. Grade III tumors are malignant and poorly-differentiated lesions. 
These tumors contain actively reproducing abnormal cells and invade surrounding normal 
tissue. Grade III tumors frequently recur, often as grade IV tumors. Grade IV tumors are the 
most malignant and invade wide areas of surrounding normal tissue. These tumors proliferate 
rapidly, appear very unusual under the microscope and are necrotic in the center. Necrosis is a 
central feature of the highest-grade malignant gliomas, and it can arise from vascular 
thrombosis, or in response to hypoxia (reviewed in Brat and Van Meir, 2004). Grade IV 
tumors also show neoangiogenesis (formation of new blood vessels), to help maintain their 
rapid growth. 
 
According to the WHO classification, astrocytic tumors are divided in four prognostic grades 
based on their histological features: grade I (pilocytic astrocytoma), grade II (diffuse 
astrocytoma), grade III (anaplastic astrocytoma) and grade IV (glioblastoma) (Louis et al., 
2007). Oligodendrogliomas and oligoastrocytomas are graded as grade II or grade III 
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(anaplastic tumors). The embryonal tumors, medulloblastomas and CNS primitive 
neuroectodermal tumors, are the most common malignant (grade IV) tumors in children. 
Schwannomas are benign (grade I) tumors arising from Schwann cells. Most meningiomas 
are benign grade I tumors, but can sometimes progress into grade II or grade III tumors. The 
specific characteristics of CNS tumors are discussed below in more detail. 
 
2.4.1 Astrocytomas (WHO grade I-IV) 
 
Pilocytic astrocytomas (grade I) are well-circumscribed, slow-growing gliomas with low 
mitotic activity. They occur predominantly in children and young adults. They can develop in 
the cerebellum, hypothalamus, optic nerves, brainstem, cerebellar hemispheres, and spinal 
cord. These tumors are generally non-aggressive, and do not usually develop into more 
malignant tumor types. Pilocytic astrocytomas have a biphasic histological pattern of compact 
and loose tissue. They may also contain features of microvascular proliferation, nuclear 
atypia, and meningeal infiltration. No diagnostically useful cytogenetic or molecular markers 
have been identified in pilocytic astrocytomas, but there is evidence that neurofibromatosis 1 
gene (NF1), and possibly also TP53, play a role in the pathogenesis of these tumors (Gray et 
al., 2003). Pleomorphic xanthoastrocytoma (PXA) is a well-circumscribed, grade II cortical 
astrocytoma, which occurs primarily in children and young adults. PXAs are composed of 
different cell types, and express astrocytic (GFAP) and neuronal (synaptophysin, 
neurofilament) markers. Characteristic molecular genetic alterations in PXAs have not been 
identified. 
 
Diffusely infiltrating astrocytomas constitute 10% to 15% of all astrocytic neoplasms in 
adults. These grade II tumors include three histological variants; fibrillary astrocytomas, 
gemistocytic astrocytomas and protoplasmic astrocytomas. Characteristic molecular changes 
include TP53 mutations (about 50% of the cases), overexpression of PDGF and its receptor 
PDGFR , and LOH of chromosome 22 (Gray et al., 2003). 
 
Grade II astrocytomas often progress to aggressive anaplastic astrocytomas (grade III). These 
tumors show increased cellularity, nuclear atypia and mitotic activity, and many of them show 
GFAP expression and increased levels of proliferation marker Ki-67/MIB-1. Many genes of 
the cell-cycle pathway, including cyclin-dependent kinase (CDK) and retinoblastoma 1 (RB1) 
genes are inactivated in these tumors, and LOH of chromosome 19 is often present (Gray et 
al., 2003). Two recent studies also described the mutations of icocitrate dehydrogenase 1 
(IDH1) gene in 70-80% of both low-grade and high-grade astrocytomas, suggesting that 
IDH1 mutations are very early events in glial tumorigenesis and may affect a common glial 
precursor cell population (Watanabe et al., 2009; Yan et al., 2009). 
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Glioblastoma (grade IV) is a progressive, malignant and fatal astrocytic neoplasm. 
Glioblastomas are the most common primary brain tumors, accounting for 40% to 50% of all 
glial tumors. Glioblastomas can occur in all age groups, and they can arise in any region of 
the CNS (Gray et al., 2003). The histologic and pathologic features include increased cellular 
proliferation, diffuse infiltration, necrosis, robust angiogenesis, intense resistance to 
apoptosis, and genomic instability. 
 
Glioblastomas can be divided into two main subtypes; primary and secondary glioblastomas 
(reviewed in Ohgaki and Kleihues, 2007). Primary glioblastomas usually occur in patients 
older than 50 years as aggressive, highly invasive tumors, usually without any evidence of 
prior clinical disease. Secondary glioblastomas are less common, and are diagnosed in 
younger patients. They result as a progression of low-grade or anaplastic astrocytomas into 
more malignant glioblastomas within 5-10 years of the initial diagnosis of lower grade 
astrocytoma. Both glioblastoma subtypes show frequent LOH 10q (63-70%), but differ 
significantly in respect to the frequency of other genetic alterations. Primary glioblastomas 
typically show epidermal growth factor receptor (EGFR) mutations and amplification, 
phosphatase and tensin homolog (PTEN) mutations, murine double minute 2 (MDM2) 
amplification, and cyclin-dependent kinase inhibitor 2A (CDKN2A) deletion (reviewed in 
Ohgaki and Kleihues, 2007). Amplification of EGFR occurs in 40% of these tumors, and all 
tumors with EGFR amplification also show EGFR overexpression. Secondary glioblastomas 
are characterized by mutations in the TP53 tumor suppressor gene, overexpression of 
PDGFR , LOH 19q, LOH 22q, and aberrations in the cell-cycle and RB genes. Despite the 
genetic differences, primary and secondary glioblastomas are morphologically 
indistinguishable; they show microvascular proliferation and pseudopalisading necrosis, and 
are composed of highly infiltrative, less well-differentiated cells that than low-grade gliomas. 
However, they show different responses to conventional and molecularly targeted therapies. 
The different pathways leading to formation of primary and secondary glioblastomas are 
illustrated in Figure 2. 
 
2.4.2 Oligodendroglial tumors (WHO grade II-III) 
 
Oligodendrogliomas (grade II) are diffusely infiltrating gliomas, accounting for 5% of all 
intracranial gliomas in adults, most often found in the cerebral hemispheres. Molecular 
characteristic include LOH 1p and 19q (in 50% to 90% of patients) (Louis et al., 2007). 
Oligodendrogliomas have generally a favourable outcome, with a median survival of 3 to 5 
years. Loss of 1p is associated with increased response to chemotherapy, and combined losses 





Anaplastic oligodendrogliomas (grade III) have a general histological appearance of 
oligodendrogliomas, but demonstrate increased cellularity, cytologic atypia, frequent mitoses, 
microvascular proliferation and necrosis. Progression from low-grade to anaplastic 
oligodendroglioma is associated with defects in PTEN, Rb, p53, and cell-cycle pathways. 
IDH1 mutations are present in 80% of oligodendrogliomas (Watanabe et al., 2009). 
Anaplastic oligodendrogliomas show remarkable sensitivity to chemotherapy. The main 
genetic and chromosomal alterations involved in the development of oligodendrogliomas are 
presented in Figure 2. 
 
2.4.3 Mixed gliomas (WHO grade II-III) 
 
Oligoastrocytomas (grade II) and anaplastic oligoastrocytomas (grade III) are composed of 
both astrocytes and oligodendrocytes, where one or both components show clearly malignant 
histology. These tumors have genotypic features of either astrocytomas or 
oligodendrogliomas, and interestingly, the astrocytic and oligodendroglial components have 
the same genetic alterations, suggesting that both cell types are derived from a single 
precursor cell (Kraus et al., 1995). Two histological subtypes of oligoastrocytomas have been 
recognized; a compact or a diffuse variant. The clinical presentation of these tumors is similar 
to those of grade II oligodendroglioma. It can be challenging to distinguish anaplastic 
oligoastrocytomas from glioblastomas, since they have many common features, including the 
presence of GFAP positive cells. Recently, IDH1 mutations were described in 90% of 
oligoastrocytomas (Watanabe et al., 2009). 
 
2.4.4 Medulloblastomas and CNS primitive neuroectodermal tumors (WHO grade IV) 
 
Medulloblastomas (MBs) are the primary brain tumors in children, but they can also occur in 
adults. These small-cell tumors arise in the cerebellum, and show high mitotic activity and 
necrosis. Several histological medulloblastoma variants exist, including desmoplastic 
medulloblastoma, medulloblastoma with extensive nodularity and advanced neuronal 
differentiation, large-cell (anaplastic) medulloblastoma, medullomyoblastoma, and melanotic 
medulloblastoma (Gray et al., 2003). The most common genetic alterations in 
medulloblastoma are loss of chromosome arm 17p, and formation of isochromosome 17q, 
which is observed in 30-50% of tumors (Bayani et al., 2000). Genetic alterations in genes 
involved in p53 and Rb pathways, as well as MYC amplification, have also been detected 
(Shakhova et al., 2006). Two hereditary syndromes are associated with medulloblastoma: 
Gorlin’s syndrome which is caused by mutation of the patched (PTCH) gene and Turcot’s 




in mismatch repair genes. These genetic aberrations implicate the roles of Shh and Wnt 
pathways in medulloblastoma tumorigenesis (reviewed in Raffel, 2004). 
 
CNS primitive neuroectodermal tumors (PNETs) are histological analogs to the 
medulloblastomas but occur in the supratentorial (cerebral) compartment. Primitive 
neuroectodermal tumors are small-cell tumors with high mitotic activity, and can demonstrate 
multiple lines of differentiation; glial, neuronal, or mesenchymal. Genetic abnormalities often 
seen in primitive neuroectodermal tumors include losses of 14q and 19q, which are present in 
40% of the tumors (Russo et al., 1999). Amplifications of MYC and EGFR genes are also 
detected (Kagawa et al., 2006). 
 
2.4.5 Schwannomas (WHO grade I) 
 
Schwannomas are benign tumors arising from Schwann cells, and they occur predominantly 
at age 40 to 60 years. They can be found on cranial nerves, spinal nerve roots, and peripheral 
nerves. Intracranial schwannomas can occur in cranial nerves (Gray et al., 2003). 
Schwannomas are well-circumscribed tumors showing low progression. Inactivation of 
neurofibromatosis 2 gene (NF2), which is seen in 50% of the tumors and leads to loss of 
merlin expression, is a crucial step in the tumorigenesis of schwannomas (Jacoby et al., 1994). 
 
2.4.6 Meningiomas (WHO grade I-III) 
 
Meningiomas are common brain tumors with a wide biologic and histological spectrum. They 
are most likely originating from the arachnoidal cap cells, or their progenitors. Meningiomas 
are derived from the meningeal coverings of the brain and spinal cord, and they account for 
13% to 25% of primary intracranial tumors and 25% of intraspinal tumors (Gray et al., 2003). 
They are predominantly found in females, and the maximal incidence is around 45 years. 
Most meningiomas are slowly growing, benign tumors (grade I), however, atypical (grade II) 
and anaplastic (grade III) meningiomas also exist. The formation of grade I meningiomas is 
associated with mutations of the NF2 gene and subsequent inactivation of its gene product 
merlin. Tumor progression into more malignant anaplastic meningioma involves losses of 
chromosome 1 and 14 (Leone et al., 1999). Anaplastic grade III meningiomas are rare, they 
are often invasive, metastatic and recurrent, and their median survival is about 2 years. 
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Figure 2. Genetic and chromosomal alterations involved in the development of glioblastomas 




3 COMMONLY ALTERED MOLECULAR PATHWAYS IN CNS TUMORS 
 
Malignant transformation in gliomas results from the sequential accumulation of genetic 
aberrations in oncogenes and tumor suppressor genes, which are components of the cell cycle 
and apoptosis pathways. Oncogenes (MDM2, PIK3CA) typically encode for proteins 
controlling cell growth and differentiation, and become hyperactivated in cancer. Tumor 
suppressor genes (TP53, RB1, PTEN) are often inactivated in tumor cells, and they can be 
divided in three groups; gatekeepers, caretakers, and landscapers. Gatekeepers inhibit cell 
proliferation in normal genes, whereas caretakers repair DNA damage (Kinzler and 
Vogelstein, 1997). Landscapers are genes that regulate the tumor microenvironment (Kinzler 
and Vogelstein, 1998). Dysregulation of receptor tyrosine kinase-mediated pathways, which 
are involved in cell growth, survival and migration, is also common in gliomas. The most 
common molecular pathways altered in CNS tumors are discussed below. 
 
3.1 The p53 pathway 
 
The tumor protein 53 (TP53) gene at chromosome 17p encodes a 53-kDa protein (p53) that 
plays an important role in several cellular processes, including the cell cycle, response to 
DNA damage, cell death, differentiation, and neovascularization (reviewed in Bögler et al., 
1995). Mutations in TP53 are seen in all grades of astrocytic tumors, and it is detected in 
about 28% of primary and 65% of secondary glioblastomas (Ohgaki et al., 2004). TP53 gene 
mutation has been shown to occur in the early stage of progression to secondary GBM (Ishii 
et al., 1999; Shiraishi et al., 2002) , but do not affect the survival of the patients (Shiraishi et 
al., 2002).  MDM2 promotes the transactivational silencing and degradation of p53 (Momand 
et al., 1992; Haupt et al., 1997), and its amplification has been shown to correlate with shorter 
survival time, suggesting that MDM2 oncogene activation occurs late in tumor progression 
and may be used as a negative prognostic marker in glioma patients (Schiebe et al., 2000). 
MDM2 gene amplifications are present in approximately 10% of malignant gliomas 
(Reifenberger et al., 1995), and amplification of MDM2 and TP53 mutations are mutually 
exclusive (Shiebe et al., 2000). Loss of p53 is not sufficient to induce formation of brain 
tumors, but may cooperate with other genetic alterations to facilitate tumor formation (Bögler 
et al., 1999). 
 
3.2 The Rb pathway 
 
The retinoblastoma 1 gene (RB1) maps to chromosome 13q14, and encodes the 
retinoblastoma protein (pRb), major regulator of cell cycle progression. In the quiescent cells, 




related genes and preventing progression through the G1/S restriction point. pRb is 
phosphorylated by cyclin-dependent kinase (CDK)/cyclin D complexes, which leads to its 
release from E2F transcription factor, activation of E2F-responsive genes, and subsequent 
entry into S phase. The dysregulation of the cell cycle can occur due to the mutational 
inactivation of RB or CDK inhibitors (CKIs), downregulation of CKI levels, or amplification 
and overexpression of CDKs or cyclin D (reviewed in Sherr, 1996). The most important CKIs 
are CDKN2A and CDKN2B, which are encoded by tumor suppressor genes CDKN2A and 
CDKN2B, respectively (Quelle et al., 1995). CDKN2A inhibits the CDK/cyclin D complexes 
from phosphorylating pRb and ensures that pRb maintains its break on the cell cycle (Serrano 
et al., 1993). CDKN2B controls cell cycle G1 progression by binding to CDKs and preventing 
their activation (Simon et al., 1999). Mutations or deletions of CDKN2A and CDKN2B result 
in disruption of growth control pathways, and are commonly seen in human gliomas (Biernat 
et al., 1997; Simon et al., 1999). The alterations in RB and CDK genes are often present in 
glial tumors, and they are also mutually exclusive (Schmidt et al., 1994; Ueki et al., 1996). 
 
Deregulation of the Rb pathway leads to dramatic increase in proliferation, and it is involved 
in transformation from low-grade to high-grade gliomas. RB mutations have been detected in 
25% of high-grade astrocytomas, and amplification of CDK4 has been observed in 15% of 
high-grade gliomas (Reifenberger et al., 1994). Inactivation of CDKN2A occurs in 30-50% of 
primary glioblastomas (Olopade et al., 1992; Fukushima et al., 2006) and in 4% of secondary 
glioblastomas (Biernat et al., 1997). 
 
3.3 LOH on chromosome 10 and PTEN 
 
LOH 10 is the most frequent alteration in glioblastomas, occurring in 60-80% of cases (Daido 
et al., 2004). Many glioblastomas appear to have lost one entire copy of chromosome 10, but 
several studies have identified at least three commonly deleted loci, 10p14-15, 10q23-24, and 
10q25-pter, suggesting the presence of several tumor suppressor genes at chromosome 10 
(Karlbom et al., 1993; Ichimura et al., 1998). LOH 10q occurs at similar frequencies in 
primary and secondary glioblastomas, but LOH 10p is commonly seen only in primary 
glioblastomas (Fujisawa et al., 2000). 
 
PTEN (phosphatase and tensin homolog) is a tumor suppressor gene mapped into the long 
arm of chromosome 10 (10q23) (Li et al., 1997). PTEN is involved in numerous signaling 
pathways linking growth factors and ECM signaling to cell survival (reviewed in Yamada and 
Araki, 2001). PTEN possesses both protein phosphatase activities and 3´-phosphoinositol 
phosphatase activities (Myers et al., 1997), and it is known to regulate growth factor signaling 




1998). PI3Ks are a family of kinase heterodimers with separate p85 regulatory and p110 
catalytic subunits (reviewed in Wymann and Pirola, 1998). The activated PI3Ks 
phosphorylate phosphatidylinositol-4,5-bisphosphate (PIP2) to phosphatidylinositol-3,4,5-
triphosphate (PIP3), which promotes activation of downstream effector molecules such as Akt 
(also called protein kinase B, PKB). This results in cell proliferation and increased cell 
survival by inhibition of apoptosis (Kennedy et al., 1997; del Peso et al., 1997; Brunet et al., 
1999). In normal cells, PTEN reduces Akt activation and makes cells more likely to undergo 
apoptosis (reviewed in Cantley, 2002), whereas tumor cells lacking PTEN are resistant to 
apoptosis and more likely to form tumors. In glioblastomas, reduced levels of PTEN and 
increased Akt activity are correlated with more aggressive tumor behaviour and reduced 
survival times in patients (Davies et al., 1998; Ermoian et al., 2002), and activation of Akt 
pathway contributes to progression of anaplastic astrocytoma (grade III) to glioblastoma 
(grade IV) in a human glioma model (Sonoda et al., 2001). PTEN can also contribute to 
tumorigenesis by reducing Rb function (Paramio et al., 1999), and it is important in regulating 
cell migration and invasion by directly dephosphorylating focal adhesion kinase (FAK). 
PTEN gene is mutated in approximately 30-44% of high-grade gliomas (Wang et al, 1997). 
 
Loss of PTEN is not sufficient to initiate tumor formation on its own, but it facilitates tumor 
formation in the presence of additional genetic lesions (Xiao et al., 2005). In several studies, 
LOH 10q has been associated with poor patient survival, while PTEN mutations show no 
association with poor prognosis. These studies suggest that another unidentified tumor 
suppressor gene on chromosome 10q may be involved in the pathogenesis of glioblastomas. 
One of the candidate genes is Mxi1 (Max interactor 1), a member of Mad family proteins, 
which is a potent antagonist of Myc oncoprotein in vivo (Schreiber-Agus et al., 1998). Mxi1 
locates at 10q24-26, and allelic loss of Mxi1 has been demonstrated in high-grade tumors 
(Ichimura et al., 1998; Wechsler et al., 1997), supporting the idea that Mxi1 could act as a 
tumor suppressor in gliomas. Another candidate tumor suppressor gene is DMBT1 (for 
deleted in malignant brain tumors 1), which locates at 10q25-26, and is deleted in 
medulloblastoma cell lines (Mollenhauer et al., 1997), glioblastomas, and anaplastic 
astrocytomas (Lin et al., 1998). 
 
PIK3CA gene, which encodes the p110α catalytic subunit of PI3K, has been shown to be 
frequently altered either by mutations or amplification in a variety of human neoplasms 
(reviewed in Karakas et al., 2006). Gain-of-function mutation of PIK3CA gene that leads to 
constitutive kinase activity has been reported in primary (5%) and secondary (3%) 
glioblastomas (Kita et al., 2007). PIK3CA amplifications occur in 12% of primary and 9% of 





4 GENETIC ABNORMALITIES ON CHROMOSOME LOCUS 4q12 IN CNS 
TUMORS 
 
Chromosome locus 4q12 harbors receptor tyrosine kinase genes KIT, PDGFRA and VEGFR2, 
as well as genes involved in neuronal development (REST, LNX1) (Figure 3). Genetic 
alterations, including gene amplification, LOH, and gain-of-function, have been detected on 
this locus in a subset of nervous system tumors (Schröck et al., 1994; Joensuu et al., 2005; 
Puputti et al., 2006). However, activating mutations in these genes have not been described 
(Hartmann et al, 2004; Sihto et al., 2005). Gene amplification is a very effective mechanism 
for upregulation of protein expression. Coamplification of genes on locus 4q12 is often seen 
in nervous system tumors, but the amplicon size and degree of amplification in individual 
tumors varies considerably (Holtkamp et al., 2007). Comparative genomic hybridization 
analysis by Ruano et al. revealed two amplicons in chromosome 4; the other contains RTKs 
KIT, PDGFRA and VEGFR2 in the center of the amplicon, the other contains SLA/LP, STIM2 
and two unknown gene sequences; the relevance of these genes in nervous system tumors is 
unknown (Ruano et al., 2006). KIT/PDGFRA/VEGFR2 amplicon is flanked with other 
amplified genes, such as LNX1, RASL11B and CHIC2 (Ruano et al., 2006; Holtkamp et al., 
2007). 
 
In addition, the chromosomal locus 4q12 harbors other interesting genes with neural functions 
(Figure 3). CLOCK regulates neuronal differentiation of adult NSC (Kimiwada et al., 2009), 
whereas NMU is a neuropeptide expressed in hippocampal regions and is implicated in 
feeding, inflammation, pain control and anxiety-related behaviours (reviewed in Brighton et 
al., 2004). The homeobox gene GSX2 is required for the normal development of the ventral 
telencephalon, and also for the retinoid production, which is involved in differentiation of 
specific neuronal subtypes (Waclaw et al., 2004). The tyrosine kinase fusion protein FIP1L1-
PDGFRA, which results from a cryptic interstitial deletion, also locates at this region. 
FIP1L1-PDGFRA fusion gene is a recurrent molecular lesion in eosinophilia-associated 
myeloproliferative disorders and systemic mastocytosis, but it has also been detected in CNS 
tissues (Williams et al., 2008). 
 
This section describes the important roles of RTKs KIT, PDGFRA and VEGFR2, as well as 



































Figure 3. The colocalization of genes with neural function on human chromosome band 
4q12. 
 
4.1 Receptor tyrosine kinases 
 
Recent advances in the cellular and molecular biology of gliomas have enhanced our 
understanding of the role of RTKs and RTK-mediated signal transduction pathways in tumor 
initiation, maintenance, angiogenesis, and vascular proliferation. RTKs and their downstream 
signaling pathways have been established as the primary oncogenic drivers in multiple glioma 
subtypes, and multiple RTKs are activated simultaneously in glioblastomas (Stommel et al., 
2007) Constitutive activation of RTKs can occur via gene amplification, overexpression, and 
activating mutations, or via activation of autocrine growth factor/receptor loops (reviewed in 
Kolibaba and Druker, 1997). Genetic alterations affecting RTK signaling results in the 
activation of several downstream pathways, and may lead to malignant cell transformation 
and tumor proliferation. 
 
RTKs constitute a family of at least 20 subfamilies. RTKs contain an extracellular ligand 
binding domain, a single transmembrane region, juxtamembrane (JM) domain, and a C-
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terminal intracellular tyrosine kinase domain (reviewed in Ullrich and Schlessinger, 1990). 
The extracellular domain may be composed of variable number of immunoglobulin (Ig) 
homology domains, cysteine-rich domains, fibronectin type III domains or leucine-rich 
domains, among others. Ligand (growth factor or hormone) binding leads to receptor 
dimerization and subsequent autophosphorylation of multiple intracellular tyrosine residues in 
the kinase domain and the C- terminal tail. These phosphorylated residues can then serve as 
docking sites for specific signaling molecules with Src homology 2 (SH2) and 
phosphotyrosine binding (PTB) domains. These molecules in turn activate many signaling 
cascades, which control the most fundamental cellular processes, including the cell cycle, cell 
migration, cell metabolism and survival, as well as cell proliferation and differentiation. The 
most often altered RTKs in glial tumors belong to EGFR-, PDGFR- or VEGFR-families 
(reviewed in Maher et al., 2001). These RTK families and their signaling in human gliomas 
are discussed in more detail below. 
 
4.1.1 EGF/EGFR subfamily 
 
The epidermal growth factor (EGF) family includes EGF, transforming growth factor-  
(TGF- ), heparin-binding EGF-like growth factor, amphiregulin, betacellulin and epiregulin 
(reviewed in Yarden, 2001). EGFR family consists of four receptors: EGFR, HER2, HER3 
and HER4. EGFR becomes activated when growth factors bind to its extracellular domain. 
The activation of a variety of intracellular signaling cascades by EGFR, including PI3K/Akt 
and Ras/mitogen-activated protein kinase (MAPK) pathways, results in cell proliferation and 
increased cell survival. The EGF family and its ligands are variably expressed throughout the 
embryogenesis, brain development and adulthood, and are involved in proliferation, 
migration, differentiation and survival of all CNS cell types and their precursors (reviewed in 
Wong and Guillaud, 2004). 
 
EGFR is a key signaling pathway in the development of primary glioblastomas. EGFR gene 
amplification and protein overexpression are more commonly seen in primary glioblastomas 
(40-60%) than in secondary glioblastomas (< 10%) (Watanabe et al., 1996). EGFR 
amplification is associated with older age, and is not detected in patients younger than 35 
years (Ohgaki et al., 2004). Glioblastomas express both EGFR and its ligands EGF and TGF-
α, suggesting the presence of an autocrine growth stimulatory loop in these tumors (Ekstrand 
et al., 1991). In glioblastomas, EGFR overexpression is almost always associated with EGFR 
gene amplification (Wong et al., 1987; Ekstrand et al., 1991). 
 
Rearrangements of the amplified EGFR gene result in translation of aberrant EGFRs. The 
most common EGFR mutations in glioblastomas are EGFRvII, EGFRvIII and EGFRvV. 
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Approximately half of the gliomas with EGFR amplification express the mutated variant 
EGFRvIII, which lacks the extracellular ligand binding domain and show constitutive 
autophosphorylation of the receptor. Overexpression of mutant EGFRs in astrocytes has been 
shown to promote the development of glioblastoma in mice (Holland et al., 1998), and 
introduction of the mutated receptor into glioma cells dramatically enhances their 
tumorigenity through increased proliferation and reduced apoptosis (Nagane et al., 1996). 
 
4.1.2 PDGF/PDGFR subfamily 
 
PDGFs and PDGFRs 
 
Platelet-derived growth factors (PDGFs) and their cognate receptors (PDGFRs) play an 
important role in regulation of normal CNS development, as well as in tumorigenesis of 
gliomas. The PDGF family consists of four ligands, PDGF-A, PDGF-B, PDGF-C and PDGF-
D. PDGFs can form homodimers, and PDGF-A and PDGF-B can also form heterodimers, 
which bind PDGFRs with varying affinities (Kelly et al., 1991). In addition to PDGFR family 
members PDGFR  (PDGFRA) and PDGFRβ (PDGFRB), this subfamily also includes KIT 
and colony-stimulating factor 1 receptor (CSF1R). These receptors belong to class III RTKs, 
which have five Ig-domains in the extracellular domain, a single transmembrane domain, and 
a tyrosine kinase domain split in two by an 80 amino acid (aa) insert region (reviewed in 
Roskoski, 2005a) (Figure 4). PDGF receptors  and β can homo- and hetero-dimerize into 
, β, and ββ combinations. The ligand-mediated receptor dimerization and 
autophosphorylation leads to activation of several signaling cascades, including PI3K/Akt, 
Ras/MAPK, Src family kinase, and phospholipase C-γ (PLC-γ) signal transduction pathways 
(Valius and Kazlauskas, 1993; Ding et al, 2003). 
 
PDGF-A is expressed in neurons throughout the adulthood, whereas PDGF-B expression in 
neurons is more limited. During mouse development, PDGFR  is expressed by 
neuroepithelial cells from E8.5 (Andrae et al., 2001), whereas PDGF-A is thought to function 
later in development as a potent mitogen of oligodendrocyte precursor cells (Calver et al., 
1998). PDGF-B and PDGFRβ are critical for vascular development, and PDGF-B is 
expressed by vascular endothelial cells, whereas PDGFRβ is expressed on vascular smooth 
muscle cells and pericytes. Mouse studies indicate that PDGFs are also important in 
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Figure 4. Structure of the receptor tyrosine kinases KIT and PDGFR , which belong to the 
subfamily of type III RTKs. KIT and PDGFR  are comprised of an extracellular (EC) domain 
with five immunoglobulin (Ig)-like repeats, a single transmembrane (TM) domain, a 
juxtamembrane (JM) domain, and an intracellular, catalytic kinase domain interrupted by a 
kinase insert domain. (Modified from Müller et al., 2008). 
 
KIT and SCF 
 
PDGF signaling has an important role in formation of brain tumors, and overexpression of 
PDGF/PDGFR has been observed in >80% of oligodendrogliomas and in 50-100% of 
astrocytomas (Guha et al., 1995; Varela et al., 2004). Overexpression of PDGFR  has been 
detected in both low- and high-grade tumors, suggesting that activation of PDGF pathway 
may be important for tumor initiation (Hermanson et al., 1996). In addition, the increased 
expression is often correlated with higher tumor grade (Nister et al., 1988; Di Rocco et al., 
1998), and may predict poor overall survival (Varela et al., 2004). Coexpression of PDGF and 
PDGFR in the same tumor cell indicates the presence of both autocrine and paracrine loop in 
these tumors (Hermanson et al., 1992).  Autocrine PDGF signaling can induce 
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oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo 
(Uhrbom et al., 2000; Dai et al., 2001). Amplification and/or overexpression of PDGFR  are 
mostly seen in oligodendrogliomas, whereas PDGFRβ expression has been detected in 
metastatic medulloblastomas, where it could be considered as a prognostic marker of poor 
overall survival (Gilbertson and Clifford, 2003). PDGFR  is also involved in tumor 
angiogenesis and could be used as a target for antiangiogenic therapy (Plate et al., 1992a). 
 
The v-kit oncogene was identified in 1986 as the transforming gene in the Hardy-Zuckerman 
4 feline sarcoma virus (Besmer et al., 1986). This virus carried a truncated v-Kit gene. The 
cellular counterpart, c-kit, was identified shortly after that (Yarden et al., 1987) in White 
spotting mice (W mice), where KIT receptor and its ligand, stem cell factor (SCF), are 
encoded at the White Spotting (W) and Steel (Sl) loci, respectively. Mutations on W locus lead 
to defects in hematopoiesis, gametogenesis and melanogenesis, and the mice manifest coat 
color depigmentation, sterility, severe macrocytic anemia, and mast cell deficiency (reviewed 
in Hamel and Westphal, 1997). The complete absence of KIT is lethal. KIT has a diverse 
range of biological functions, and it plays an important role in melanogenesis, hematopoiesis, 
erythropoiesis, as well as in spermatogenesis (Ray et al., 1991; Matthews et al., 1991; Kapur 
et al., 1998; Yoshinaga et al., 1991). As a result of alternative mRNA splicing, different 
isoforms of KIT have been identified. Two of these isoforms are characterized by the 
presence or absence of four amino acids (GNNK) just outside the plasma membrane (Reith et 
al., 1991). These isoforms have the same affinity for their ligand SCF (Serve et al., 1995), but 
the GNNK- isoform displays more rapid and extensive tyrosine autophosphorylation and 
faster internalization than GNNK+ isoform (Voytyuk et al., 2003). 
 
The ligand of KIT, SCF (also known as KIT ligand, KL, or steel-factor), binds to the second 
and third immunoglobulin domain, and the fourth domain plays a role in receptor 
dimerization (Lev et al., 1993; Zhang et al., 2000) (Figure 4). Binding of SCF dimer to the 
extracellular domains of two receptor monomers brings them together and produces a receptor 
dimer, thus activating KIT receptor and triggering the autophosphorylation of a number of 
tyrosine residues, mainly located outside the kinase domains (Figure 5). The phosphorylated 
tyrosine residues serve as docking sites for signal transduction molecules containing SH2 or 
PTB domains (reviewed in Pawson, 2004). These molecules include adaptor protein APS, Src 
family kinases, and Shp 2 tyrosyl phosphatase, which bind to phosphotyrosine 568 in the JM 
domain (Mori et al., 1993). Shp1 tyrosyl phosphatase binds to phosphotyrosine 570, also in 
the JM domain. The kinase insert domain binds adaptor protein Grb2 (Tyr703), PI3K 
(Tyr721), and PLC-γ (Tyr730). Adaptor proteins APS, Grb2 and Grb7 can also bind to 






































Figure 5. Schematic illustration of the KIT receptor and interacting proteins. Ligand (SCF) 
binding to KIT leads to receptor dimerization and activation of its intrinsic tyrosine kinase 
activity. The phosphorylated tyrosine residues serve as binding sites for various cell signaling 
proteins. The numbers refer to phosphorylated tyrosine residues, and the corresponding signal 
molecules are denoted. SFK, Src family kinases; SHP2, SH2-containig protein tyrosine 
phosphatase (Modified from Lennartson et al., 2005). 
 
The signaling cascades activated by KIT are involved in cell survival, proliferation, 
differentiation, and chemotaxis. These pathways include the PI3K/Akt, PLC-γ, Ras/MAPK, 
Janus kinase (JAK)/signal transducer and activator (STAT), and the Src signaling pathways 
(Roskoski et al., 2005b). PI3K/Akt is one of the major downstream pathways of KIT 
responsible for mediating cell growth, and activation of PLC-γ cascade has been linked to 
proliferation and invasion of the tumor cells (Khoshyomn et al., 1999; da Rocha et al., 2000). 
Ras/MAPK pathway is important for mitogenic responses to many growth factors and for 
survival of the cells. KIT-mediated activation of JAK phosphorylates STATs, which induce 
cell proliferation, differentiation, migration, and apoptosis (Brizzi et al., 1994; DeBerry et al., 























Figure 6. Signaling cascades activated by KIT. Ligand (SCF) binding to KIT and the 
subsequent dimerization and autophosphorylation of the receptor results in cell proliferation 
and inhibition of apoptosis through several pathways, including PI3K/Akt, Ras/MAPK, Src, 
and JAK/STAT cascades. Raf, v-raf-1 murine leukemia viral oncogene homolog; Shc, Src 
homology 2 domain containing transforming protein; MEK, mitogen-activated protein kinase 
kinase; SOS, Son of Sevenless, a guanine nucleotide exchange factor 
 
In the adult mouse cerebellum, KIT mRNA and protein are expressed in the basket, stellate, 
and Golgi interneurons, which are local circuit neurons constituting the molecular and 
granular layers. KIT and SCF are also expressed in Purkinje cells, which are the principal 
neurons in the cerebellum, suggesting that KIT/SCF pathway plays a role in postnatal 
development of the cerebellum (Manova et al., 1992; Zhang and Fedoroff, 1999). In vitro, 
KIT/SCF signaling regulates the activity of astroglia, oligodendroglia, and microglia (Ida et 
al., 1993; Zhang and Fedoroff, 1997; Zhang and Fedoroff, 1998) and KIT and SCF expression 
levels are upregulated in microglia in response to brain injury (Zhang and Fedoroff, 1999). 
KIT is thought to play an important role in maintaining the survival and functionality of 




shown to be a useful marker for identification of undifferentiated murine embryonic stem 
cells (ESC) (Palmqvist et al., 2005). 
 
Gain-of-function mutations of KIT are associated with several human neoplasms including 
acute myelogenous leukemia (AML), gastrointestinal stromal tumors (GIST), mastocytomas, 
nasal T-cell lymphomas, and seminomas/dysgerminomas (reviewed in Heinrich et al., 2002). 
Activating KIT mutations occur in the extracellular, the juxtamembrane, and the proximal and 
distal kinase domains. However, no activating KIT mutations have been detected in gliomas 
(Sihto et al., 2005). KIT and its ligand SCF are coexpressed in some non-hematopoietic 
tumors, such as small-cell lung cancer, myeloid leukemia and breast cancer (Hibi et al., 1991; 
Pietsch et al., 1992; Turner et al., 1992; Ulivi et al., 2004), and also in neuroblastomas (Cohen 
et al., 1994), suggesting the presence of a KIT/SCF autocrine loop in these malignancies. 
 
SCF is a key survival and growth factor for the self-renewal, proliferation and differentiation 
of numerous embryonic, foetal, umbilical cord and adult hematopoietic, neural and primordial 
stem cells (Hassan, 2008). SCF can exist as a membrane associated form or as a soluble form 
(Huang et al., 1992). The membrane-associated form lacks the proteolytic cleavage site and 
remains associated with the cell surface, whereas the soluble form is rapidly released from the 
plasma membrane through proteolysis (soluble form). Stimulation with the soluble form 
results in rapid but transient autophosphorylation of KIT, whereas stimulation with the 
membrane-bound form results in more sustained phosphorylation (Miyazawa et al., 1995; 
Zhang et al., 2000). The production of different SCF isoforms seems to be regulated in a 
tissue-specific manner, and most of the SCF in brain is in the soluble form (Huang et al., 
1992), predominantly produced by neurons (Zhang and Fedoroff, 1997). 
 
SCF is overexpressed by neurons following brain injury, and it mediates NSC migration to 
the site of cerebral injury (Zhang and Fedoroff., 1999; Jin et al., 2002; Sun et al., 2004; 
Erlandsson et al., 2004). In primary human gliomas, SCF is expressed in a grade-dependent 
manner, and it may have a role in tumor-induced angiogenesis (Sun et al., 2006). 
Downregulation of SCF inhibits tumor-mediated angiogenesis and glioma growth in vivo, 
whereas overexpression of SCF is associated with shorter survival of patients with malignant 
gliomas. Thus, SCF could be a potentially important therapeutic target for malignant gliomas. 
 
4.1.3 VEGF/VEGFR subfamily 
 
The human vascular endothelial growth factor (VEGF) family consists of VEGF (VEGF-A), 




comprises three protein tyrosine kinases (VEGFR1, VEGFR2, and VEGFR3) and two non-




VEGF was originally described as a vascular permeability factor based on its ability to induce 
vascular leakage (Ferrara and Henzel, 1989; Connolly et al., 1989). VEGF is a mitogen and 
survival factor for vascular endothelial cells (Alon et al., 1995; Gerber et al., 1998), and it 
also promotes vascular endothelial cell and monocyte motility (Clauss et al., 1990). VEGF 
signaling is a key player in vasculogenesis (formation of new blood vessels from embryonic 
hemangioblasts) and angiogenesis (formation of blood vessels from pre-existing vascular 
networks by capillary sprouting) (reviewed in Ferrara, 2005), as well as developmental 
hematopoiesis (reviewed in Gerber and Ferrara, 2003). VEGF-C and VEGF-D promote 
angiogenesis and lymphangiogenesis (Veikkola et al., 2001), whereas the biological role of 
VEGF-B is poorly characterized. PlGF is mostly expressed in the placenta and can also 
induce angiogenesis (Ziche et al., 1997) 
 
VEGF is expressed by tumor cells (Dvorak et al., 1991), including brain tumor cells (Plate et 
al., 1992b; Huang et al., 2005). VEGF signaling is thought to occur in a paracrine fashion, so 
that VEGF secreted by neoplastic cells activate the VEGFRs expressed by nearby endothelial 
cells (Dvorak et al., 1991). VEGF induces several signal transduction pathways, including 
PLC-γ, PI3K/Akt, and Src (Guo et al., 1995; reviewed in Matsumoto and Mugishima, 2006). 
Expression of VEGF mRNA is up-regulated in low-grade gliomas and is very high in 
glioblastomas, where the expression is strongest in hypoxic tumor cells adjacent to necrotic 
areas (Plate et al., 1992b; Ikeda et al., 1995).  VEGF is important in tumor angiogenesis 
during glioma progression, and expression of VEGF can be used as a prognostic marker of 
these tumors (Yao et al., 2001). VEGF expression has been detected also in other glial 





VEGFR1, VEGFR2 and VEGFR3 belong to class V receptor tyrosine kinase subfamily, 
which consists of an extracellular part containing seven immunoglobulin-like domains, a 
single transmembrane domain, a JM segment and a cytoplasmic kinase domain interrupted 
with a kinase-insert domain of 70-100 aa (Shibuya et al., 1990). VEGFR1 and VEGFR2 are 
expressed in the cell surface of most blood endothelial cells, while VEGFR3 expression is 




VEGFR1 and VEGFR2 
 
VEGFR1 (fms-like tyrosine kinase-1, Flt1) binds to VEGF, VEGF-B, and PlGF (Park et al., 
1994; Olofsson et al., 1998). VEGFR1 undergoes weak tyrosine autophosphorylation in 
response to VEGF (Waltenberger et al., 1994), suggesting that VEGFR1 is not the main 
receptor transmitting the mitogenic signal, but rather a decoy receptor, preventing VEGF 
binding to VEGFR2 and thus negatively regulating the activity of VEGF (Park et al., 1994).  
 
VEGFR2, also known as kinase-insert domain receptor (KDR) and fetal liver kinase-1 (Flk1), 
is thought to be the major mediator of the mitogenic and survival, as well as angiogenic and 
microvascular permeability-enhancing effects of VEGF in endothelial cells (Terman et al., 
1992; Shalaby et al., 1995; Gerber et al., 1998). VEGFR2 is mainly activated by VEGF, but 
proteolytically cleaved VEGF-C and VEGF-D can also activate this receptor (reviewed in 
Kowanetz and Ferrara, 2006). VEGFR2 receptor activates several signaling cascades, 
including PLC-γ, PI3K, Ras/MAPK, and Src pathways (Guo et al., 1995; Eliceiri et al., 1999). 
VEGFR2 is also expressed by hematopoietic progenitor/stem cells (HSC) and mature 
endothelial cells (reviewed in Rafii et al., 2002). 
 
Expression of VEGFR1 and VEGFR2 is upregulated by hypoxia (Gerber et al., 1997; Nilsson 
et al., 2004), and it has been shown to contribute to tumor angiogenesis (reviewed in Ferrara 
et al., 2007; Laakkonen et al., 2007).  VEGFR1 expression is seen in endothelial cells of both 
low- and high-grade gliomas, whereas VEGFR2 expression is limited to endothelial cells of 
high-grade gliomas (Plate et al, 1994; Hatva et al., 1995). Upregulated expression of VEGF, 
VEGFR1 and VEGFR2 has been detected also in pilocytic astrocytomas (Leung et al., 1997). 
 
VEGFR3 and neuropilins 
 
VEGFR3 (fms-like-tyrosine kinase 4, Flt4) is a receptor for VEGF-C and VEGF-D (Achen et 
al., 1998), and it is known to play a role in lymphangiogenesis (Laakkonen et al., 2007), but 
also in angiogenesis (Veikkola et al., 2001). VEGFR3 is upregulated by hypoxia in vascular 
endothelial cells in tumors (Valtola et al., 1999; Bando et al., 2004; Nilsson et al., 2004), and 
its expression has been shown to positively correlate with tumor grade (Grau et al., 2007). 
 
Neuropilins 1 and 2 are transmembrane non-protein tyrosine kinase co-receptors for the 
VEGF and semaphorin families. Neuropilin 1 enhances the binding of VEGF to VEGFR2, 
and is also able to bind VEGFR1 (Soker, 2001). Neuropilin 1 is required for vascular 
development and it mediates VEGF-dependent angiogenesis (Lee et al., 2002), whereas 






REST is a repressor element RE1 binding factor, also known as a neuron-restrictive 
silencer/regulator factor (NRSF). It is a zinc finger transcription factor, which contains two 
repressor domains in the N- and C-terminal parts, and a DNA binding domain consisting of 
eight zinc-finger motifs. REST can bind to the 21-23-bp consensus repressor element (RE1) 
sequences in a number of genes via the zinc-finger motifs (Chen et al., 1998). This binding 
silences the transcription of several neuronal and non-neuronal differentiation genes. There 
are ~1900 copies of RE1 elements in human genome, which encode neurotransmitters, growth 
factors, and ion channels, among others (Bruce et al., 2004). Zinc finger transcription factors 
are important for normal cell growth and differentiation, and aberrations in their function can 
lead to neoplastic growth and formation of tumors (Ruppert et al., 1991; Ye et al., 1993). 
 
REST is essential for embryonic development and regulation of neuronal gene expression. 
During embryogenesis, it is ubiquitously expressed in non-neuronal cells and ESCs (Ballas et 
al, 2005; Sun et al., 2005), where it represses the expression of neuron-specific genes. As 
progenitors differentiate into neurons, the transcription of REST is blocked and neuronal 
genes are activated (Ballas et al., 2005). However, REST expression is also observed in 
certain mature neurons in adults (Koenigsberger et al., 2000), suggesting that it is either 
reexpressed or that its expression is maintained in a specific type of neurons. It has been 
suggested that REST prevents differentiation and maintains the self-renewal and pluripotency 
of stem cells (Ballas et al., 2005; Singh et al., 2008), whereas two other reports argue that 
REST is not required for maintaining the ESC pluripotency (Jørgensen et al., 2009; Buckley 
et al., 2009). These controversial results indicate that REST has a complex role in regulation 
of neuronal development, and its deregulation may cause several abnormalities. 
 
4.3 LNX1 and Numb protein family 
 
LNX1, a ligand of Numb protein X, is a protein with intrinsic E3 ubiquitin ligase activity. It 
acts as a molecular anchor protein for Numb family proteins (Dho et al., 1998; Rice et al., 
2001), and may function to localize Numb to its appropriate intracellular site with its 
functionally related proteins (Xie et al., 2001). LNX1 contains four PDZ domains, which are 
conserved, 90 aa protein motifs that can interact directly with other PDZ domains to form 
both homomeric and heteromeric complexes (Xie et al., 2001). Interactions of PDZ domains 
with plasma membrane and cytosolic proteins play a role in connecting intracellular signal 
transduction pathways (reviewed in Kornau et al., 1997). LNX1 can regulate the Notch-Numb 
interactions via its N-terminal, cysteine-rich RING finger domain (Chen et al., 2005). The 




in ubiquitylation and proteasomal degradation of Numb proteins (Nie et al., 2002), which may 
lead to activation of Notch signaling and induction of tumorigenesis (Pece et al., 2004). In 
normal adult brain, high levels of LNX1 expression has been detected in mouse hippocampal 
neurons (Rice et al., 2001). The role of LNX1 in brain tumorigenesis is largely unknown, but 
one study shows the downregulation of LNX1 expression in gliomas (Chen et al., 2005). In 
addition, overexpression of LNX1 has been shown to enhance cell migration and promote 
epithelial to mesenchymal transition (Nie et al., 2009). 
 
Numb family proteins Numbl, also know as Numblike (located at chromosome 19q13), and 
Numb, were first identified as the mammalian homologs of Drosophila numb. Numb 
functions during asymmetric neural precursor cell division (Rhyu et al., 1994) and plays an 
essential role in cell fate decisions in the peripheral and central nervous systems (Park et al., 
1998). During neurogenesis, precursor cells undergo asymmetric divisions that generate 
neurons and progenitor cells. Numb/Numbl segregates asymmetrically to progenitor cells and 
plays an important role in the maintenance of neural progenitor cells during embryonic 
neurogenesis (Petersen et al., 2002; Li et al., 2003; Petersen et al., 2004). However, Numb 
also seems to have a role in promoting neuronal differentiation, and it is possible that it has 
different functions at different times, and may depend on the cellular context (Zilian et al., 
2001). Numbl mRNA is highly enriched in neurons of the embryonic nervous system (Zhong 
et al., 1997), and it is also involved in maintaining SVZ homeostasis by regulating ependymal 
integrity and survival of SVZ neuroblasts (Kuo et al., 2006). It also maintains the proper 
morphogenesis of cerebral cortex, since inactivation of Numbl leads to disorganized cortical 
lamination (Zhong et al, 2000; Rasin 2007). Loss of Numbl causes impaired neuronal 
differentiation and defects in cortical morphogenesis (Li et al., 2003). 
 
In addition, loss of Numbl expression leads to activation of Notch, and altered Notch 
signaling has been linked to many diseases, including cancer (reviewed in Nam et al., 2002). 
Notch is a plasma membrane receptor involved in cell fate determination and proliferation and 
differentiation of NSCs (Apelqvist at al., 1999; De Bellard et al., 2002). Numbl can bind to 
Notch intracellular domain via its N-terminal PTB domain, and antagonize Notch function in 
a poorly characterized mechanism (Guo et al., 1995; Zhong et al., 1997). Since Notch is 
activated through a series of proteolytic cleavages leading to the release of its soluble 
intracellular domain, it is possible that binding of Numb to Notch prevents nuclear 
translocation and hence transcriptional activity of this domain (Pece et al., 2004). Numbl can 
also interact with Mdm2 via the PTB domain. Through its interaction with Numb, Mdm2 may 
influence processes such as differentiation and survival, which could contribute to the altered 




5 TREATMENT STRATEGIES FOR MALIGNANT GLIOMAS 
 
Malignant gliomas are among the most aggressive types of human cancers. Major 
breakthroughs in the treatment of these tumors have not been achieved, and the prognosis of 
malignant gliomas has remained poor. Recurrence following current standard treatments, 
surgery, radiation therapy and adjuvant chemotherapy, is nearly inevitable. Maximal surgical 
resection of tumors significantly improves survival (Lacroix et al., 2001), and novel radiation 
therapies, boron neutron capture and proton therapy may increase the accuracy of 
radiotherapy (Kawabata et al., 2009; Combs, 2009). Blood-brain barrier (BBB) restricts the 
delivery of the chemotherapies and small molecule inhibitors to the tumors, and several 
agents have been used to disrupt the BBB, such as mannitol and hydroxyurea (Dogruel et al., 
2003). Therapy with temozolomide (TMZ), an orally-available methylating agent used in 
silencing of O-6-methylguanine-DNA methyltransferase (MGMT) promoter, has become the 
standard for treating patients with newly diagnosed tumors (Stupp et al., 2005). In 
combination with radiotherapy, TMZ has been shown to increase the survival time of the 
patients (Martinez et al., 2007). Several combination trials of TMZ with other small molecule 
inhibitors are ongoing (www.clinicaltrials.gov/). Specific gene amplifications, activating gene 
mutations and overexpressed proteins may be useful as therapeutic targets for glioma. Lately, 
several small molecule inhibitors of RTKs and their pathways have been developed. The 
major completed or ongoing clinical trials are listed in Table 1. 
 




The EGFR family was the first growth factor receptor used as a target for glioma therapy. 
Several tyrosine kinase inhibitors directed to EGFR have been developed and tested. Gefitinib 
(Iressa ) is a small molecule inhibitor of EGFR, which has been tested in treatment of 
glioblastoma patients with EGFR overexpression (Mellinghoff et al., 2005). The clinical trials 
have now proven gefitinib ineffective as monotherapy in high-grade glioma patients 
(Lassman et al., 2005). Erlotinib (Tarceva ) is another EGFR kinase inhibitor, which has 
shown modest efficacy in glioma patients when used as monotherapy or in combination with 
TMZ. Erlotinib is effective in patients who coexpress the truncated, constitutively active 
EGFRvIII and PTEN (Mellinghoff et al., 2005), or show high expression of EGFR and low 
levels of pAkt (Haas-Kogan et al., 2005). Cetuximab (Erbitux ), an antibody against EGFR, 
has shown some antitumor activity alone or in combination with radiation therapy in patients 
with EGFR amplification (Combs et al., 2007). Other EGFR targeted drugs under 





Imatinib mesylate (Glivec ) interacts with an inactive conformation of KIT, PDGFR  and 
PDGFRβ. It inhibits the activity of selected tyrosine by blocking the adenosine triphosphate-
binding site and eliminating the source of the phosphate group needed for their activity 
(Heinrich et al., 2000; Tuveson et al., 2001). Other cellular targets of imatinib include the 
activated forms of Abelson protein tyrosine kinase Abl, Bcr-Abl (Carroll et al., 1997), and 
CSF1R (Guo et al., 2006). In mice, imatinib is able to reduce ESC survival and cell-cycle 
progression, as well as increase apoptosis, most likely by targeting KIT function (Lu et al., 
2007). Imatinib also sensitizes glioma cells to radiation injury (Russell et al., 2003). However, 
phase II trials of imatinib have not shown efficacy in treatment of glioma patients (Wen et al., 
2006; Raymond et al., 2008), but combination of imatinib and hydroxyurea has shown some 
promising results in minority of patients (Dresemann, 2005; Reardon et al., 2005; Desjardins 
et al., 2007). A phase I trial with imatinib in combination with TMZ has also shown some 
efficacy in glioma patients (Reardon et al., 2008). The efficacy of other PDGFR-family 
targeted drugs, such as sorafenib (Nexavar ), sunitinib (Sutent ), dasatinib (Sprycel ) and 




Neoangiogenesis, the formation of new blood vessels, is one of the hallmarks of cancer 
(Folkman, 1971), and it has been demonstrated experimentally to be important for glioma 
progression (Plate et al., 1994). This has lead to a development of anti-angiogenic therapies 
which target the ligands or receptors of VEGF pathways, the key players in angiogenesis 
(reviewed in Sathornsumetee and Rich, 2007b). VEGF is secreted by glioma cells, whereas 
tumor-associated endothelial cells express its receptor VEGFR2, thus creating a paracrine 
loop. Bevacizumab (Avastin®), a humanized antibody against VEGF (Kim et al., 1993; 
reviewed in Hurwitz, 2004), is commonly used in combination with cytotoxic chemotherapy 
(topoisomerase I inhibitor irinotecan), and it has been shown to reduce the tumor 
microvascularity and prolong the progression-free survival of glioma patients (Vredenburgh 
et al., 2007; Poulsen et al., 2009; Kreisl et al., 2009). Several clinical trials of bevacizumab in 
combination with radiation therapy, chemotherapy, or other targeted agents are ongoing.  
Small-molecule dual-inhibitors of PDGFR-family and VEGFR1/VEGFR2, such as sunitinib 
and vatalanib have shown modest efficacy in clinical models (Fong et al., 1999; Goldbrunner 
et al., 2004; Conrad et al., 2004), whereas combination therapy of vatalanib with alkylating 





Clinical practice reveals that anti-angiogenic therapy often does not prolong survival of 
cancer patients for more than a few months, and two recent papers have demonstrated that 
anti-angiogenic treatments leads to increased invasion and metastasis in mouse models (Pàez-
Ribes et al., 2009; Ebos et al., 2009). Resistance to continuing anti-angiogenic treatment 
might upregulate other proangiogenic factors, such as PDGF-C, PlGF, Tie2, and bFGF, which 
have been implicated in angiogenesis and/or metastasis of tumors (Crawford et al., 2009; 
Batchelor et al., 2007; Willett et al., 2005). Furthermore, there is also evidence that anti-
angiogenic therapy can mobilize circulating endothelial cells or their precursors, thus 
supporting angiogenesis (Batchelor et al., 2007; reviewed in Kerbel, 2008). Anti-VEGF 
therapy in a rat model of glioblastoma resulted in decreased tumor vessel density and 
increased apoptosis. However, treatment also led to the increased invasiveness into the normal 
brain tissue and cooption of host vessels, thus circumventing the necessity of the tumor to 
initiate angiogenesis (Rubenstein et al., 2000). Some data suggest that combination of VEGF 
and PDGFR inhibition might result in greater anti-angiogenic activity (reviewed in Bergers 
and Benjamin, 2003). 
 
Table 1. Major molecularly targeted completed or ongoing clinical trials in gliomas 
 

















































Rich et al., 2004 
Prados et al., 2009 
Combs et al., 2006 
 
Reardon et al., 2005 
Reardon et al., 2009 
 
Vredenburgh et al., 2007 
Conrad et al, 2004 
 
Study no. NCT00606008 
Study no. NCT00379080 
 
Galanis et al., 2005 
 
Study no. NCT00597493 






5.2 Future directions in glioma treatment 
 
The treatment of malignant gliomas remains one of the most challenging areas in oncology. 
The existence of several parallel or compensatory oncogenic pathways in gliomas is very 
challenging when developing new therapies, since inhibition of a single specific pathway may 
result in the activation of a compensatory pathway which may allow the tumor cell to survive. 
The clinical trials using targeted monotherapy have failed, or show only modest efficacy, 
most likely due to inefficacy of the agents to reach their target, or due to the failure of tumor 
cells to undergo apoptosis, which leads to tumor recurrence. 
 
Several strategies have been developed to circumvent the poor response to current targeted 
agents. Such strategies include new target identification, improved drug delivery, inhibition of 
multiple targets by multitargeted inhibitors or new treatment combinations, biomarker 
identification, and development of reliable preclinical models. The first-generation targeted 
drugs, which inhibit only one or a few kinases, have generally failed to demonstrate survival 
benefit as monotherapies. At the moment, none of these targeted drugs are approved for 
clinical use in the treatment of glioma patients. New generation small molecule inhibitors 
targeting multiple aberrant signaling cascades or molecules along the same pathway may offer 
synergistic action and prevent drug resistance (Traxler et al., 2004; Goudar et al., 2005; 
O´Farrell et al., 2003). The disadvantage of these multitargeted kinase inhibitors is the 
increased toxicity. Inhibitors targeting several other protein kinases, such as mTOR and Raf, 
and their pathways, are also under investigation (Hjelmeland et al., 2007). 
 
Other investigational approaches that have demonstrated promise in preclinical and early 
clinical studies include gene therapy, oncolytic virotherapy, and immunotherapy. These 
strategies can be aimed to replace or correct the genetic alterations responsible for the 
malignant phenotype, induce apoptosis, or enhance immunity. Gene therapy strategies use 
viral vectors to deliver therapeutic transgenes directly to tumor cells within the CNS (Lawler 
et al., 2006). One possible strategy is to replace the “loss of function” in a tumor-suppressor 
gene (such as TP53). Another strategy is to use suicide gene therapy, which employs 
oncolytic viruses for delivery of pro-apoptotic genes to induce cell death (Arafat et al., 2003).  
Delivery of the herpes simplex virus thymidine kinase gene into tumor cells and the 
subsequent administration of ganciclovir has showed some promising preclinical results 
(reviewed in Hamel and Westphal, 2003). However, viral vectors have a number of 
theoretical and practical limitations, and the use of genetically modified stem cells seem to be 





Oncolytic virotherapy utilizes replication competent viruses to specifically infect and lyse 
tumor cells. Three human pathogenic viruses are used in this approach; herpes simplex virus, 
adenovirus, and poliovirus, which are tumor-specific replication-restricted viruses, and can be 
genetically engineered based on their target tropism. Immunogene therapy involves the 
genetic manipulation or enhancement of the immune system machinery to attack and kill 
tumor cells. Vaccination with professional antigen presenting cells known as dendritic cells 
(DCs) primed with tumor antigen ex vivo may induce a systemic T-cell response and tumor 
cell destruction (Liau et al., 2005). Phase I and II clinical trials of DC vaccination have 
demonstrated cytotoxic effects in some patients (Yu et al., 2004; Yamanaka et al., 2005). 
 
Individualized and tailored therapies are likely to change glioma treatment strategies. The use 
of multitargeted-kinase inhibitors may overcome the resistance of tumors to single-agent 
targeted therapies. However, it will require identification of molecular and genetic profiles of 
tumors and correlative biomarkers of response or resistance to targeted therapies. Future 
glioma treatment strategies will also combine molecularly targeted therapies with radiation, 
chemotherapies, and immunotherapies. Strategies to enhance delivery of therapeutic agents 
into the CNS, such as nanoparticles (Veiseh et al., 2009), may also increase the efficacy.  
Finally, the role of CSCs in glioma tumorigenesis needs to be further evaluated. Targeting 







AIMS OF THE STUDY 
 
The chromosomal locus 4q12 harbors several genes (KIT, PDGFRA, VEGFR2, REST, LNX1) 
implicated in glial tumorigenesis. The aim of this study was to analyze the role of these genes 
in human nervous system tumors using clinical tumor material. Furthermore, the role of KIT 
in glial tumorigenesis was investigated using several in vitro functional assays. The anti-




The specific aims were: 
 
1. To study the genetic and protein expression status of genes on chromosome locus 4q12 in 
human nervous system tumors 
 
2. To analyze the gene amplification and overexpression of receptor tyrosine kinases KIT, 
PDGFRA and VEGFR2 in human medulloblastomas 
 
3. To investigate the consequences of lentivirus-mediated KIT overexpression in cultured 
astrocytes 
 
4. To investigate the growth inhibitory effects of small molecule inhibitor imatinib in 

























Tumor type               ntot  Grade                   Used in           
  
 
Medulloblastoma            41  IV                  I, II, III 
CNS PNET             11  IV                      III 
Schwannoma              5  I                     I, II 
Meningioma              8  I                     I, II 
Diffuse/anaplastic astrocytomas    349  II-IV               I, II, III, IV 
Oligoastrocytoma           39  II-III                      I, II 
Oligodendroglioma           59  II-III                      I, II 
Primary glioblastoma           74  IV                      I, II 




Cell line               Description  Source                   Used in 
 
 
C8-D1A           Mouse astrocyte type II cell line  ATCC  IV 
HEK-293FT             Human embryonic kidney fibroblast 
                                  cell line expressing the simian            
                                  virus 40 large T antigen ATCC    IV 
HUVEC           Human umbilical vein endothelial      ATCC  IV 
                                  cell line 
M07-e           Myeloid leukemia cell line DSMZ  IV 








pLenti5/V6  Empty vector (mock) Invitrogen  IV 
pLenti5/V6/KIT Encodes human KIT IV  IV 
pLenti5/V6/GFP Encodes Aequorea victoria    
green fluorescent protein IV  IV









Antigen  Primary antibody Source                   Used in 
 
 
nestin  Mouse monoclonal Chemicon  I 
p53  Mouse monoclonal Novocastra  I 
KIT  Rabbit polyclonal DAKO  III 
PDGFRA  Rabbit polyclonal  CST  III 
VEGFR2  Rabbit monoclonal CST  III 
GFAP  Rabbit polyclonal Chemicon  IV 
KIT  Mouse monoclonal Labvision  IV 
pKIT (Y703)  Rabbit polyclonal Biosource  IV 
Ki-67  Mouse monoclonal Novocastra  IV 
β-tubulin  Rabbit monoclonal Labvision  IV 




Secondary antibodies   Source                  Used in 
 
 
FITC-conjugated goat anti-rabbit  Rockland  IV 






Target gene  Probe ID  Source                  Used in 
 
 
REST  RP11-1005B7  Invitrogen  I 
LNX1  RP11-809n18  Invitrogen  II 
NUMBL  RP11-825A10  Invitrogen  II 
KIT  RP11-97763  Invitrogen                         II, III, IV 
PDGFRA       RP11-117E8  Invitrogen  III 
VEGFR2  RP11-662M13 Invitrogen  III

















Descriptions of the methods used in this study are found in the original publications (I-IV) as 
indicated in the table below. 
 
Method             Used and described in 
 
 
Soft agar assay     IV 
Cell culture      IV 
cDNA synthesis     IV 
Cell proliferation assay     IV 
Chromogenic in situ hybridization (CISH)    I, II, III 
Confocal microscopy     I, II, III, IV 
Denaturing high pressure liquid chromatography (DHPLC)  I, II 
DNA subcloning     IV 
DNA/RNA extraction     I, II, IV 
Flow cytometric analysis (FACS)    IV 
Fluorescence in situ hybridization (FISH)    I, IV 
Immunofluorescence     IV 
Immunohistochemistry     I, II, III, IV 
Polymerase chain reaction (PCR)    I, II 
Real-time quantitative PCR     IV 
Sequencing      I, II 
Statistical analysis (Prism 4, SPSS)    I, II, III, IV 
Western blotting     IV 
Wound healing assay     IV 
Transduction of cells     IV 
Transfection of cells     IV 






















RESULTS AND DISCUSSION 
 
The results of these studies are summarized and discussed here. The original publications are 
referred to by Roman numerals. 
 
1 Genetic aberrations and overexpression of genes at 4q12 in human nervous system 
tumors (I, II, III) 
 
This thesis work describes the genetic aberrations of multiple genes at the chromosomal 
segment 4q12 in nervous system tumors. Mutations or SNPs of REST, LNX1 and NUMBL 
genes were observed in a variety of nervous system tumors. Coamplification of KIT, 
PDGFRA, VEGFR2 and LNX1 genes was seen especially in glioblastomas, and it was often 
associated with poor overall survival. Interestingly, the gene amplification did not always 
result in protein overexpression. Increased protein expression may be restricted to tumors 
with very high gene copy numbers (Joensuu et al., 2005; Holtkamp et al., 2007). Other 
mechanisms, such as transcriptional factors, may also play a role. In conclusion, these data 
implicates that the genetic instability at 4q12 play an important role at least in a subset of 
nervous system tumors. The gene mutation, amplification and protein expression data of this 
work is presented in Tables 2-4. Further analyzes are required to identify the extension of this 
gene amplicon, and the functional contribution of individual genes. The elucidation of the 
affected signaling pathways in more detail may help to target and improve the therapy of 
nervous system tumors. 
 
1.1 REST gene mutations and amplification (I) 
 
REST has been implicated in a variety of diseases, including neurological diseases and cancer 
(Zuccato et al., 2003; Westbrook et al., 2005). REST expression has been detected in human 
medulloblastomas and neuroblastoma cells (Palm et al., 1999; Lawinger et al., 2000; 
Watanabe et al., 2004; Fuller et al., 2005), where it is thought to have an oncogenic role. 
Furthermore, concomitant overexpression of Myc and REST in NSCs causes tumors in mouse 
cerebellum (Su et al., 2006), and these tumors are morphologically similar to human 
medulloblastomas. These studies suggest that the abnormal overexpression of REST in 
neuronal cells blocks these cells from terminal neuronal differentiation and produces the 
cancerous phenotype, perhaps by forcing the cells to persist in a stem/progenitor state. 
 
Interestingly, REST has been shown to act as a tumor suppressor gene in human mammary 
epithelial cells and colorectal cancer, and small-cell lung carcinoma (Westbrook et al., 2005; 




or as an oncogene, depending on the cellular context (reviewed in Majumder, 2006). These 
studies indicate that REST is an important regulator of neural development, and due to its 
chromosomal location next to the receptor tyrosine kinase genes KIT, PDGFRA and VEGFR2, 
we analyzed its possible role in glial tumorigenesis. 
 
In this work, mutations in REST exons 1-3 were successfully analyzed from 161 samples 
obtained from patients with nervous system tumors. The tumor material included astrocytic 
and oligodendrocytic tumors of different grades, as well as medulloblastomas, meningiomas 
and schwannomas. Altogether, DHPLC analysis and subsequent sequencing revealed eight 
single nucleotide polymorphisms (SNPs) in REST gene; the genetic alterations were found in 
one primary glioblastoma, one secondary glioblastoma, one anaplastic astrocytoma, one 
oligoastrocytoma (grade III), three oligodendrogliomas (grade III), and one meningioma. All 
SNP variants were located at exon 3, either at position 797 or 815 (Figure 7a). The 
homozygotic REST SNP at position 797 causes an amino acid change of proline to leucine 
(P797L), and heterozygotic SNP at position 815 causes an amino acid change of proline to 
serine (P815S). The SNP status was also associated with higher tumor grade (P = 0.0147). 
Mutation screening of control samples from anonymous blood donors revealed the SNP 
variant P815S in one of 96 samples, whereas P797L variant was absent in the control 
samples. However, this SNP variant has been reported previously in four population studies 
(www.ensembl.org). To our knowledge, our effort to screen REST alterations in nervous 
system tumors is the first and only in the literature. The found variants localize at the N-
terminal proline-rich area of REST, in the PPAK motif found in elastic protein titin, and 
which may also have protein kinase activity. The alterations in REST gene may cause changes 
in the biochemical properties of the REST protein and affect its binding to target DNA. 
 
In order to study the occurrence of gene copy number changes, FISH was used to analyze 
REST copy numbers in one meningioma and ten glioblastomas. Low-level amplification (3-5 
gene copies per one chromosome) of REST gene was observed in four glioblastomas (36%) 
and in the meningioma sample. One of the primary glioblastoma samples harbouring the 
P815S SNP variant had high-level amplification (>5 gene copies per one chromosome) of 
REST (Figure 7b). Additionally, 36 secondary glioblastomas and 13 medulloblastomas were 
analyzed for REST copy numbers by CISH. In glioma samples, high-level amplification of 
REST was found in one (6%) oligodendroglioma (Figure 7c), and low-level amplification was 
seen in 24 (67%) tumor samples. Low-level amplification or aneuploidy (2-3 copies per one 
chromosome) was seen in five (38%) medulloblastomas. At the time this study was done, no 
properly working antibodies against REST were available, thus the immunohistochemical 





The location of REST at 4q12 implies that it may be a part of the earlier mentioned 
KIT/PDGFRA/VEGFR2 amplicon. Amplification of REST could lead to overexpression of the 
protein, and possibly trigger the development and progression of malignant growth. Abnormal 
expression of REST could repress the transcription of terminal differentiation genes, leading 
to accumulation of undifferentiated cells, and eventually in tumor formation. Overexpression 
of REST is a common finding in medulloblastomas (Fuller et al., 2005), indicating that REST 
may have a significant role in these tumors. Our data suggests that high-level amplification of 
REST occurs only infrequently in gliomas, and no high-level amplification was seen in 
medulloblastomas. However, due to the limited amount of tumor material available, we 
cannot conclude that high-level amplifications of REST do not exist. We suggest that the 
molecular genetic alterations of REST may not directly underlie glioma tumorigenesis, but 
REST may contribute to the tumor development beyond the DNA level. 
 
As a regulator of many neuronal cells, alterations in REST function could be an important 
factor in initiation and growth of tumors arising from neural stem/progenitor cells. Nestin is a 
commonly used marker for NSCs, and it has been found to be expressed in brain tumor 
initiating cells as well (Bexell et al., 2009). We analyzed the expression of nestin in glioma 
tissue samples (n = 105), and we found strong cytoplasmic-membranous nestin expression in 
ten gliomas (one diffuse and three anaplastic astrocytomas, one oligodendroglioma, two 
oligoastrocytomas, and three glioblastomas). Strong cytoplasmic-membranous and 
endothelial nestin staining was detected in 24 gliomas (five diffuse and four anaplastic 
astrocytomas, four oligodendrogliomas, five oligoastrocytomas, and six glioblastomas). 
Expression of nestin in gliomas may indicate the neural stem/progenitor cell origin of 
neoplastic cells. Five of the seven gliomas with REST SNPs were nestin positive, but in our 
limited tumor material no clear correlation was found between nestin expression and SNP 
status in general. 
 
Inactivation of TP53 combined with an acquisition of multipotency might be an important 
step in development of malignant gliomas. A previous study demonstrated that cell lines 
derived from the brains of the TP53-deficient mouse embryos showed upregulation of REST 
(Horiuchi et al., 2005), and inactivation of TP53 increased self-renewal of NSCs (Meletis et 
al., 2006). The nervous system tumor samples harboring REST SNPs were analyzed for p53 
protein expression and gene mutations. Three of the seven samples were p53 positive, but no 
mutations were observed. These findings suggest that alterations of TP53 and REST genes are 










Figure 7. Two polymorphic variants of REST gene in exon 3. Homozygotic variant P797L 
was found in oligodendroglioma, and heterozygotic variant P815S was detected in 
glioblastoma. The arrows show the base substitution C/T in the variants (a). High-level 
amplification of REST in glioblastoma was detected by FISH (b). Seven gene copy signals 
(red) and two chromosome 4 centromere signals (green) are detected in the nucleus. High-
level amplification of REST in oligodendroglioma analyzed by CISH (c). 
 
1.2 LNX1 and NUMBL gene mutations and amplification in nervous system tumors 
(II) 
 
LNX1 and Numb/Numbl are components of the mammalian Notch signaling cascade, which 
regulates several cellular processes (reviewed in Lundkvist and Lendahl, 2001). 
Downregulation of Numb and subsequent activation of Notch pathway have been detected in 
breast carcinomas (Pece et al., 2004) and medulloblastomas (Di Marcotullio et al., 2007), 
suggesting that Numb acts as a tumor suppressor. However, an oncogenic role for Numb has 




of astrocytomas, being stronger in high-grade than low-grade astrocytomas (Yan et al., 2008). 
Numb is ubiquitylated and targeted for degradation by LNX1, and downregulation of LNX1 
expression has been previously demonstrated in both low-grade and high-grade gliomas 
(Chen et al., 2005). These results imply that Numb functions as an oncogene and may be 
involved in glial tumorigenesis. 
 
In this study, the genetic status of LNX1 and NUMBL in human nervous system tumors was 
investigated by mutation and copy number analyses. Gene mutations were successfully 
analyzed from LNX1 exons 1-10 and NUMBL exons 2-10 from 90 tumor samples, consisting 
of 53 primary glioblastomas, 4 secondary glioblastomas, 8 astrocytomas, 10 
oligodendrogliomas, two medulloblastomas, eight meningiomas, and five schwannomas. 
Additionally, 245 glioma samples (21 primary glioblastomas, 30 secondary glioblastomas, 63 
astrocytomas, 43 anaplastic astrocytomas, 49 oligodendrogliomas, and 39 oligoastrocytomas) 
were screened for mutations in LNX1 exon 3. DHPLC analysis and subsequent sequencing 
revealed missense mutations in LNX1 exons 3 and 5, and intronic changes (SNPs) in exons 1, 
7 and 10. LNX1 exon 3 mutations, which cause an amino acid change of alanine to valine 
(A227V), were seen in one primary glioblastoma (1%), in one astrocytoma (1%), and in one 
meningioma (13%). LNX1 mutations, which cause an amino acid change of arginine to 
histidine (R428H), were seen in one primary glioblastoma (2%), in one astrocytoma (13%), 
and in one oligodendroglioma (10%). The intronic C/T changes in LNX1 exon 1 were found 
in two primary glioblastomas (4%) and in exon 9 in two primary glioblastomas (4%). In 
addition, intronic deletion of T in LNX1 exon 10 was seen in one primary glioblastoma (2%). 
The screening of control DNAs revealed LNX1 exon 3 mutation in one out of 24 analyzed 
samples, whereas mutations in exon 5 were not found. SNPs in LNX1 exons 1, 9 and 10 were 
not found in any databases, thus we consider these variations to be novel findings. The 
mutation screening of NUMBL revealed a previously reported, synonymous SNP variant T/C 
(Cys/Cys) in one primary glioblastoma (2%), and in one medulloblastoma (50%). A variable 
number of polyglutamine (CAG) repeats were seen in NUMBL exon 10 in three primary 
glioblastomas (6%). The locations of the observed SNPs in LNX1 and NUMBL genes are 
summarized in Figure 8. 
 
LNX1 and NUMBL gene copy numbers were successfully analyzed from 41 and 42 nervous 
system tumors, respectively. CISH analysis revealed high-level amplification of LNX1 in 
three glioblastomas and one medulloblastoma (Figure 9a). Low-level amplification (gain) was 
seen in six glioblastomas and two astrocytomas. High-level amplification of NUMBL was 
found in two glioblastomas (Figure 9b), and gains in six glioblastomas. Altogether, we found 























Figure 8. Schematic presentation of LNX1 and NUMBL gene structures and the locations of 
the mutations and SNPs found in this study (arrows). PTB, phosphotyrosine binding domain; 
SNP, single nucleotide polymorphism 
 
LNX1 and NUMBL genes are located on the chromosomal regions 4q12 and 19q13, 
respectively, which are often implicated in glial tumorigenesis (Holtkamp et al., 2007; 
Beghini et al., 2003). Our data presents that both gene sequence alterations and amplifications 
of LNX1 and NUMBL are present in a subset of gliomas, and the important role of these genes 
in neurogenesis suggests that they may contribute to development of glial tumors. Changes at 
the DNA level and in gene copy numbers of LNX1 found in this study may reflect the genetic 
instability on locus 4q12. Our results presenting the amplification of NUMBL in gliomas are 
in line with the previous results that show the expression of Numb, the homolog of Numbl, in 
astrocytomas (Yan et al., 2008), supporting the oncogenic function of Numb. The observation 
of LNX1 amplifications in nervous system tumors supports the oncogenic role also for LNX1, 
while previous reports have shown its downregulation in human gliomas and implicate that it 
acts as a tumor suppressor (Chen et al., 2005). Further studies will be needed to evaluate these 




observed, it might be possible that aberrations in LNX1 and NUMBL genes play independent 





Figure 9. High-level amplifications of LNX1 (a) and NUMBL (b) in human glioblastomas. 
The gene copy signals are seen as brown dots over the blue nuclei. 
 
1.3 Coamplification of KIT and LNX1 in nervous system tumors (II) 
 
Amplification of KIT has been observed in a subset of gliomas, and the coamplification of 
KIT with other receptor tyrosine kinase genes, PDGFRA and VEGFR2, is often detected in 
glial neoplasms (Puputti et al., 2006). In order to investigate whether LNX1 gene is also a part 
of this amplicon, we conducted a gene copy number analysis of KIT and analyzed the 
correlation with LNX1 amplification. 
 
We analyzed 51 nervous system tumors for KIT gene copy numbers using CISH. 
Amplification of KIT was observed in two glioblastomas and one medulloblastoma. Increased 
copy numbers (gains) were detected in 11 glioblastomas and two astrocytomas. The 
association of KIT amplification with LNX1 amplification was analyzed, and there was a clear 
correlation between LNX1 and KIT amplification in human glioblastomas (P = 0.02), 
suggesting a coamplification of LNX1 and KIT genes in these tumors. 
 
LNX1gene amplification status was also compared to our previously reported data of KIT, 
PDGFRA and VEGFR2 gene amplifications in human glioblastomas (Puputti et al., 2006). 
Amplification of LNX1 was correlated with KIT (P = 0.012) and PDGFRA (P = 0.001) 
amplification. These data suggest that the amplification of LNX1 gene is a part of the KIT, 
PDGFRA and VEGFR2 amplicon in human gliomas. In addition, KIT amplification showed 
tendency to correlate with VEGFR2 amplification (P = 0.066). Previously, coamplification of 
KIT, LNX1 and PDGFRA has been reported by Holtkamp et al. (2007). The coamplification 
of NUMBL with KIT, PDGFRA and VEGFR2 genes was also analyzed, but no significant 





1.4 Amplification and overexpression of KIT, PDGFRA and VEGFR2 in 
medulloblastomas and CNS primitive neuroectodermal tumors (III) 
 
Coamplification of receptor tyrosine kinases KIT, PDGFRA and VEGFR2 has been detected 
in a subset of astrocytic and oligodendroglial tumors (Joensuu et al., 2005; Puputti et al., 
2006), but their role in MB/PNET tumorigenesis remains uncertain. KIT, PDGFRA and 
VEGFR2 are located on adjacent positions on chromosome locus 4q12, a region which is 
frequently altered in gliomas. Increased copy numbers (gains) at 4q12-13 have been observed 
in MBs, but no high-level amplifications have been detected (Russo et al., 1999; Michiels et 
al., 2002). In PNETs, amplification of KIT has been reported previously (McCabe et al., 
2006), and KIT protein expression has been detected in both MBs and PNETs (McCabe et al., 
2006), but activating mutations in KIT gene were not found (Chilton-MacNeill et al., 2004). 
Aberrant PDGFRA signaling has been implicated in MB development (Andrae et al., 2002; 
Gilbertson and Clifford, 2003). Amplification of PDGFRA has been observed in PNETs 
(McCabe et al., 2006), and protein overexpression in MBs and PNETs (Smits et al., 1996). 
Some reports suggest that overexpression of PDGFRA is associated with more aggressive, 
metastatic MB (MacDonald et al., 2001; Andrae et al., 2002). However, others have shown 
that higher expression of the PDGF signaling pathway is a marker of a more favorable 
prognosis (Kool et al., 2008). VEGF and VEGFR2 have been shown to promote angiogenesis 
in human gliomas, and VEGFR2 expression has been detected in medulloblastoma cell lines, 
MBs and PNETs (Slongo et al., 2007; Huber et al., 2001), suggesting a possible autocrine role 
for VEGF in MB progression. 
 
In this work, protein expression and gene amplification of KIT, PDGFRA and VEGFR2 in 41 
MBs and 11 PNETs were investigated using immunohistochemistry and CISH, respectively. 
Since earlier reports have not demonstrated activating mutations in KIT, PDGFRA and 
VEGFR2 in brain tumors (Hartman et al., 2004; Sihto et al., 2005), we did not conduct a 
mutation screening of these genes. 
 
Immunohistochemical analysis showed strong KIT protein expression in one MB and weak 
expression in nine MBs and two PNETs. Strong or very strong PDGFRA expression was 
detected in six MBs and in one PNET. Weak PDGFRA expression was seen in seven MBs 
and in four PNETs. In our study, VEGFR2 expression in MBs and PNETs was almost absent, 
only one MB showed weak VEGFR2 expression. Statistical analysis did not show any 
correlation between KIT, PDGFRA or VEGFR2 protein expression and clinical parameters. 
High-level amplification of KIT gene was seen in one MB and in one PNET, and increased 
copy numbers (gains) of KIT were detected in 15 MBs and two PNETs. PDGFRA 




one PNET. Amplification of VEGFR2 was seen in one MB and in one PNET, and gained 
copy numbers in nine MBs and in one PNET. Statistical analysis showed a clear association 
between KIT and PDGFRA gene copy number gains (P = 0.001), and also between KIT and 
VEGFR2 copy number gains (P < 0.001). In addition, there was an association between 
PDGFRA and VEGFR2 copy number gains (P < 0.001). KIT gene copy numbers were also 
associated with sex, being more common in women (P = 0.029, n = 41). 
 
Poor overall survival was associated with PDGFRA gene copy number gains (Log-rank test, P 
= 0.027, n = 37) and VEGFR2 gains showed tendency to associate with poor clinical outcome 
(Log-rank test, P = 0.058, n = 31). The mean survival of MB/PNET patients with PDGFRA 
aneuploidy or amplification (14 cases) was 53.9 months (95%, CI 31.9-76.8), whereas the 
mean survival of patients without PDGFRA gain (23 cases) was 104.1 months (95%, CI 77.2-
131.0). In tumors with VEGFR2 aneuploidy or amplification (12 cases), the mean survival of 
MB/PNET patients was 42.3 months (95%, CI 30.2-54.4), compared to the mean survival of 
95.1 months (95%, CI 63.8-126.5) of patients without gain (19 cases). 
 
Protein overexpression and gene amplification of KIT, PDGFRA and VEGFR2 can lead to 
the activation of their downstream signaling pathways, which may be associated with 
MB/PNET development. However, there was not any significant association between KIT, 
PDGFRA or VEGFR2 protein expression and gene amplification in the present study, 
indicating that other mechanisms than gene amplification may cause protein overexpression 
in these tumors. The increase in DNA copy number does not always lead to transcriptional 
upregulation or protein overexpression, and other control mechanisms may be involved; for 
example, gene mutations and transcriptional and/or posttranscriptional factors might play a 
role (Awaya et al., 2005), and the amount of transcripts may be negatively regulated by 
promoter methylation, or depend on tumor proliferation status (Mueller et al., 2004; Durbecq 
et al., 2004). Earlier study by Holtkamp et al. demonstrated that only high copy numbers of 
KIT and PDGFRA lead to protein overexpression (Holtkamp et al., 2007). It is possible that 
PDGFRA and VEGFR2 gene copy numbers may associate with poor survival by some other, 
yet unidentified, mechanism. 
 
This study presents the coamplification of KIT, PDGFRA and VEGFR2 genes in human MBs 
and PNETs. To our knowledge, this is the first report showing the amplification of PDGFRA 
and VEGFR2 in MBs. Most strikingly, PDGFRA gain was associated with poor patient 
survival outcome. Our results are in line with earlier studies which show that PDGFRA is 
associated with the more aggressive, metastatic MB and short survival time (Andrae et al., 




hotspot for aberrant gene expression in human nervous system tumors, and could be used as a 
prognostic marker for these malignancies. 
 
Previous report shows that some MBs, and likely also some PNETs, derive from neural stem 
cells or progenitor cells, and those non-neoplastic cell populations and embryonal brain 
tumors share the same activated signaling pathways (Fan et al., 2008). Inhibition of these 
shared developmental pathways may provide a new therapeutic tool in treatment of MB 
patients. The association between KIT, PDGFRA and VEGFR2 gene aberrations and 
MB/PNET CSC properties remains to be studied. 
 
1.5 Overexpression of KIT in nervous system tumors (IV) 
 
In addition to embryonal tumors, we analyzed KIT protein expression in 235 diffusely 
infiltrating astrocytomas (grades II-IV). KIT immunoreactivity was detected in 43 
astrocytomas, either in endothelial cells (30 tumors), or diffusely in the tumor cells (14 
tumors). Endothelial and glial KIT immunopositivity was significantly associated with Ki-67 
cell proliferation index (P = 0.001), which can be considered as one of the indicators for more 
aggressive gliomas. 29% of KIT-positive patients were alive after 5-year follow-up, whereas 
17% of KIT-negative patients survived the same period (Log-rank test, P = n.s.), suggesting 


















Table 2. Gene mutations found in different types of nervous system tumors 
 
 
Tumor type                        Gene         Exon         n   nt change       AA change    Ref 
 
Medulloblastoma NUMBL 6             1 T/C Cys/Cys II 
 
Meningioma  REST 3             1 C/T Pro/Leu I 
  LNX1 3             1 C/T Ala/Val II 
 
Astrocytoma  LNX1 3             1 C/T Ala/Val II 
  LNX1 5             1 G/A Arg/His II 
 
Anaplastic astrocytoma REST 3             1 C/T  Pro/Leu I 
 
Oligoastrocytoma REST 3             1 C/T Pro/Leu I 
Oligodendroglioma REST 3             3 T/T, C/T  Pro/Ser, I 
                                                                                                             Pro/Leu 
  LNX1 5             1 G/A Arg/His II 
 
Primary glioblastoma REST 3             1 C/T Pro/Ser I 
  LNX1 3             1 C/T Ala/Val II 
  LNX1 5             1 G/A Arg/His II 
  LNX1 1, 9         4 C/T intronic II 
  LNX1 10           1 T deletion intronic II 
  NUMBL 6             1 T/C Cys/Cys II 
  NUMBL 10           1 GAG polymorphism II 
 




















Table 3. Amplification of genes on chromosome locus 4q12 in nervous system tumors 
 
 
Tumor type  Gene             Amplification                 Gain  Ref 
         n/ntot                         n/ntot 
 
Medulloblastoma KIT 2/41                  15/41 II,III 
  PDGFRA 1/41                  11/41 III 
  VEGFR2 1/41                    9/41 III
  LNX1 1/4                      ─ II 
      
   
CNS PNET  KIT 1/11                    2/11 III
  PDGFRA 1/11                    1/11 III
  VEGFR2 1/11                    1/11 III 
 
Meningioma  REST  ─                      1/1 I 
 
Astrocytoma  LNX1  ─                      2/4 II 
 
Glioblastoma REST 1/10                     4/10 I 
  LNX1 3/23                     6/23 II 
  NUMBL 2/30                     6/30 II
  KIT 2/31                   11/31 II





Table 4. Expression of KIT, PDGFRA and VEGFR2 in nervous system tumors 
 
Tumor type  Protein   High expression    Weak expression Ref 
 
 
Medulloblastoma KIT 1/41          9/41  III 
  PDGFRA 6/41          7/41  III 
  VEGFR2    ─          1/41  III 
 
CNS PNET  KIT    ─          2/11  III 
  PDGFRA 1/11          4/11  III 
  VEGFR2         ─              ─  III 
 









2 Overexpression of KIT induces proliferation and phenotypical changes in mouse 
astrocytes (IV) 
 
KIT and its ligand SCF are widely expressed in embryonic and adult mouse brain, and they 
play a significant role in many signal transduction pathways involved in cellular proliferation, 
differentiation, and cancer cell metastasis. Glial tumorigenesis and progression may be driven 
in part by CSC populations (Phillips et al., 2006), and KIT may play a role in these processes, 
since it is expressed in the glial progenitor cells (Ida et al., 1993). SCF is up-regulated in high-
grade human gliomas, leading to autophosphorylation of KIT and activation of autocrine 
growth factor/receptor loop. In addition, SCF can promote angiogenesis, and its expression is 
associated with short survival (Sun et al., 2006). SCF and KIT activation may thus have a role 
in glioma development and progression. Amplification of KIT is present in all grades of 
gliomas, and it is associated with KIT protein expression and with presence of PDGFRA and 
VEGFR2 amplifications (Puputti et al., 2006). In addition, amplified KIT is more often found 
in recurred gliomas than in newly diagnosed gliomas, suggesting that it may be involved in 
malignant progression of gliomas. However, the specific function of KIT pathway in glial 
tumorigenesis or disease progression has not been elucidated fully. 
 
In order to study the effects of KIT overexpression on cell proliferation and growth in an in 
vitro model, we introduced KIT gene into mouse astrocyte cell line using lentivirus-mediated 
gene transfer. Empty vector was used as a mock control. The effective DNA transformation 
was verified using GFP marker in fusion with KIT gene, and stable transduction of KIT into 
the cells was confirmed by FISH, which showed 1 copy of human KIT gene in the nucleus. 
Double immunofluorescence of astrocytes with anti-KIT and anti-GFAP antibodies showed 
KIT protein expression in the cytoplasm. The immunohistochemical analysis showed an 
increased expression of KIT in the transduced cell line (AstroKIT cells) compared to the 
native astrocytes. Phosphorylation of tyrosine 703 in KIT protein showed that KIT protein 
was active in these cells. Real-time RT-PCR analysis showed elevated mRNA levels of KIT 
in transduced cells, and KIT mRNA levels were increased upon stimulation with KIT ligand, 
SCF, confirming that KIT is functionally active in these cells. In addition, SCF mRNA levels 
were also upregulated in KIT overexpressing cells, implicating the presence of a KIT/SCF 
autocrine loop in AstroKIT cells. 
 
The effect of KIT overexpression on cell proliferation was analyzed by a colorimetric crystal 
violet proliferation assay, wound healing assay and FACS. After incubation for two days, the 
crystal violet staining showed that the transduced cells proliferated 1.8 times faster than native 
cells (Figure 10). The growth properties were further analyzed by wound healing assay by 
making a scratch wound across an astrocyte monolayer. After 28 hours, no prominent wound 
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was seen in AstroKIT cell monolayer, whereas for native astrocytes, twice as long time was 
needed for closing the wound. These results suggest a faster migration or proliferation of 
AstroKIT cells compared to native cells. FACS analysis showed that the G1 fraction was 
significantly higher in AstroKIT cells than in native cells. During G1 phase of the cell cycle 
the cells increase in size, and RNA synthesis occurs. Interestingly, the cell cycle profiles of 
AstroKIT cells and a commercial U-118 MG glioma cell line were similar to each other, 
suggesting that KIT overexpression in mouse astrocytes can lead to increased proliferation 
and neoplastic growth. These results are consistent with the immunohistochemical analysis, 
which shows that overexpression of KIT is associated with the expression of the proliferation 
marker Ki-67 in clinical tumor material. 
 
The essential pathways regulating apoptosis are disrupted in malignant gliomas, and this may 
contribute to their resistance to conventional pro-apoptotic chemotherapy and radiotherapy. 
Resistance to apoptosis results from changes of the cell-cycle control mechanisms, directed 
mostly by PTEN/PI3K/Akt and the Ras/MAPK signaling cascades (reviewed in Lefranc et al., 
2009). In this work, the apoptosis rate of the AstroKIT cells was analyzed by FACS. The 
results showed no difference in apoptosis rates between AstroKIT and native cells. However, 
since AstroKIT cell are proliferating faster, we suggest that the net cell number is increased in 
AstroKIT cells. Malignant gliomas are also highly invasive in nature, and their ability to 
infiltrate into the ECM makes their treatment very challenging. Matrix metalloproteinases 
(MMPs) are the major components of the enzyme cascade responsible for degradation of 
ECM, and they have been shown to contribute to the malignancy and invasion of brain tumors 
(Deryugina et al., 1997; Koul et al., 2001; Kondraganti et al., 2000). MMP-2 and MMP-9 are 
highly expressed in low- and high-grade gliomas (Nakagawa et al., 1994; Forsyth et al., 
1999). Since MMP activity is often increased in neoplastic cells, we measured the MMP-2 
and MMP-9 activities in the transduced cells by zymogram assay. Increased proteolytic 
activities of MMP-2 and MMP-9 were seen in AstroKIT cells compared to native cells. These 
results imply that KIT overexpression increases the activity of MMP-9 and MMP-2 in mouse 
astrocytes, and may promote the invasive abilities of these cells. 
 
One of the crucial hallmarks of fully transformed neoplastic cells is anchorage-independent 
growth, which is regulated by integrin-ECM interaction and growth factor signaling 
(reviewed in Wang, 2004). Transformed cells have lost their contact inhibition, and can form 
colonies in a semi-solid agar. We analyzed the malignant transformation of AstroKIT cells by 
soft agar assay. 5  103 cells were seeded in agar and the colonies were stained after 10 days. 
The results showed a 4- to 5-fold increase in the amount of colonies formed by AstroKIT cells 
compared to native cells, and the size of the colonies was also larger. 
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Most strikingly, when we analyzed the AstroKIT cells microscopically, we were able to 
observe phenotypic changes in AstroKIT cells. AstroKIT cells were rounder, larger, contained 
more prominent cytoplasm and showed fewer and shorter processes than native cells. These 
changes, especially loss of processes, may reflect the tumorigenic properties of the cells 
caused by the KIT overexpression. Our results strongly suggest that KIT has a role in 
modulating cell growth and size, and that it may contribute to neoplastic cell transformation. 
 
Taken together, our results show that KIT overexpression dramatically modulates astrocyte 
function by increasing proliferation and expression of MMPs, characteristics that are typical 
for neoplastic cells. Furthermore, KIT overexpression induces phenotypic changes in these 
cells, indicating that KIT may play a role in astrocyte growth regulation, and possibly in glial 
tumorigenesis. KIT activates several signaling pathways involved in regulation of cell growth 
and apoptosis, and the specific pathways contributing to the increased proliferation seen in 
cells overexpressing KIT remain to be elucidated. The data demonstrated here suggests an 


























Figure 10. Proliferation rates of WT, mock and AstroKIT cells with or without imatinib 
treatment was determined by crystal violet proliferation assay. Proliferation was significantly 
increased in AstroKIT cells compared to WT (*P < 0.01) or mock cells (*P < 0.01). Imatinib 







3 Effect of tyrosine kinase inhibitor imatinib on growth properties of mouse 
astrocytes with stable KIT overexpression (IV) 
 
Imatinib is a small molecule inhibitor targeting KIT, PDGFRs and BCR-ABL. In order to 
investigate the sensitivity of KIT overexpressing mouse astrocytes to imatinib treatment, we 
studied the effects of imatinib on KIT protein phosphorylation status, cell proliferation, and 
MMP activity in AstroKIT cells. 
 
Our results show that 10 µM imatinib treatment reduced the amount of phosphorylated KIT in 
AstroKIT cells, indicating that imatinib can inhibit KIT activity. The proliferation rate of 
AstroKIT cells was decreased by 49% after imatinib treatment, showing a partial growth 
inhibition (Figure 10). In addition, imatinib showed a clear dose-responsive antiproliferative 
effect on AstroKIT cells. In the wound healing assay, imatinib was able to inhibit the 
migration/proliferation of AstroKIT cells, and it significantly reduced the MMP-9 activity in 
AstroKIT cells, whereas it did have only a minor impact on MMP-2 activity levels. It has 
been shown that MMP-2 and MMP-9 are expressed in gliomas, and their expression 
positively correlates with higher tumor grade.  MMP-2 and especially MMP-9 play an 
important role in the invasiveness of gliomas, mediating the degradation of the ECM and 
angiogenesis (Wang et al., 2003). Together, these results indicate that the neoplastic growth 
properties caused by KIT overexpression can be partially inhibited by imatinib. 
 
Previously, Hägerstrand et al. have characterized a subset of imatinib-responsive primary 
glioma cell lines, which have high PDGFR expression levels, and Puputti et al. have earlier 
reported the coamplification of KIT and PDGFRA in human gliomas (Hägerstrand et al., 
2006; Puputti et al., 2006). It would be tempting to speculate if KIT and PDGFR signaling 
cascades would be linked, and further investigations are needed to elucidate these pathways in 





4 Mouse astrocytes overexpressing KIT form tumors in nude mouse brain 
(unpublished) 
 
In order to investigate whether the KIT overexpressing mouse astrocytes (AstroKIT cells) can 
form tumors in vivo, we established an orthotopic xenograft model by an intracranial injection 
of these cells into nude mouse brain using a stereotactic device. Eight mice of ten injected 
with AstroKIT cells formed tumors in the brain, and these tumors showed histologically 
similar features to glioblastomas (data not shown). The mice injected only with PBS did not 
form any tumors. Since the mouse astrocyte cell line used in this study is a commercial, 
spontaneously transformed immortal cell line, also seven of the eight mice injected with WT 
astrocytes formed tumors in the mouse brain. However, the time needed for tumor formation 
was shorter in mice injected with AstroKIT cell than in mice injected with WT cells; it took 
31 days for AstroKIT tumors to reach the volume 0.1 cm3 compared to 41 days for WT 
tumors (P = 0.0007). There was also a significant difference the survival times of these 
groups; the average survival time in WT group was 46.25 days, and in AstroKIT group 34.9 
days (P < 0.1). The immunohistochemical analysis of the tumors and characterization of the 
tumor cells are warranted for elucidating the growth properties of these tumors. These results 
indicate that KIT signaling plays an important role in glioma tumorigenesis, and new drugs 























CONCLUDING REMARKS AND PERSPECTIVES 
 
Malignant astrocytic gliomas are the most common and lethal intracranial tumors. Genetic 
and biochemical evidences have shown that glial tumorigenesis involves a stepwise 
accumulation of genetic aberrations affecting either signal transduction pathways activated by 
receptor tyrosine kinases or cell cycle growth arrest pathways. Abnormal or deregulated RTK 
signaling can occur via gene amplification and/or overexpression, and activation of autocrine 
growth factor/receptor loops. The cooperativity between RTK signaling pathways and cell 
cycle regulatory molecules in development of gliomas has been elucidated by numerous 
genetic studies and animal models, and the information can be translated into glial tumor 
treatment strategies. 
 
In this project, we conducted the genetic and expression analyses of PDGFRA, VEGFR2, 
REST, LNX1 and NUMBL using clinical material from patients with nervous system tumors. 
In addition, several in vitro experiments using mouse astrocytes were conducted in order to 
investigate the role of KIT in progression of glial tumors. Our results show that KIT, 
PDGFRA and VEGFR2 are coamplified in a subset of gliomas. Furthermore, amplification of 
PDGFRA in medulloblastomas and primitive neuroectodermal tumors is associated with poor 
patient survival. Other genes with neural functions located at this chromosomal region, such 
as REST and LNX1, may also have genetic alterations or copy number increases in a subset of 
gliomas. The concomitant amplification and overexpression of these genes in the same tumor 
samples suggest that genes at 4q12 may be a part of a more extended amplicon. Taken 
together, we conclude that the genetic aberrations on chromosomal locus 4q12 are important 
in glioma tumorigenesis and could be used in part as prognostic factors of patient survival. 
 
We also investigated the role of stem cell factor receptor KIT for cell growth properties in 
mouse astrocytes. The data presented here show that overexpression of KIT regulates the 
growth of astrocytes and induces characteristics typical of neoplastic cells, such as increased 
proliferation and proteolytic MMP activity, as well as anchorage-independent growth, 
suggesting an oncogenic role for KIT overexpression in a subset of gliomas. Furthermore, 
imatinib, the small molecule inhibitor of KIT, was able to partially inhibit the accelerated 
proliferation and reduce the MMP activity in these cells.  Our studies provide evidence that 
KIT signaling pathway may be an important player in brain tumorigenesis, either as an 
individual pathway, or converging with other key signaling cascades, such as 
PDGF/PDGFRA pathway. Future work is required for more detailed characterization of KIT 





Intensive research during last decades has lead to invention of new molecularly targeted 
therapies for treatment of malignant brain tumors, but the patient survival still remains poor. 
KIT, PDGFRs and VEGFRs are important clinical targets for tyrosine kinase inhibitors. 
Mechanisms of these important RTK signaling pathways in glial tumorigenesis needs to be 
clarified in more detail in order to develop more specifically targeted therapies for eradication 
of brain cancer. Numerous reports have recently proposed that brain cancer may arise from 
the malignant transformation of multipotent adult stem cells, or their early progenitors. 
 
Cancer stem cells isolated from brain tumors express many characteristics of neural 
stem/progenitor cells, and mutations of key regulatory elements within the pathways which 
modulate growth and differentiation of neural progenitor cells during development are also 
associated with development of gliomas. One of the major challenges now is to determine 
whether the brain tumors originate from accumulating oncogenic events occurring in the 
neural stem cells, or whether they arise from more committed and differentiated precursors 
with stem-cell like properties. The presence of drug-resistant cancer stem cells makes the 
treatment of malignant gliomas challenging, but may also provide an excellent tool for 
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